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A rough estimation puts the number of cells 
making up a human body to about 1014, or 
one hundred thousand billion cells. These 
cells all stem from only one ancestor, the 
fertilized egg, or zygote, which carries in 
its DNA, folded neatly into chromosomes, 
all information necessary to build that 
body. With hundreds of different cell types, 
creating many different tissues all having 
to be developed and maintained it is not 
hard to imagine that sometimes errors 
arise. All cells in a multicellular organism 
are altruistic, they exist to support the 
germ cells (these will form the gametes, or 
sperm and eggs), which will give rise to the 
next generation. A fundamental difference 
between a normal cell and a cancer cell 
is that the latter loses its altruistic nature; 
cancer cells display selfish behaviour in 
that they don’t listen to signals (to stop 
proliferation) from their neighbours any 
more, compete for nutrients and invade 
into new tissues disregarding their 
social rules and destroying them while 
reproducing.
Cancer cells often resemble their normal 
counterparts but differ through the 
presence of a series of genetic alterations, 
or mutations, that deregulate several 
regulatory circuits that govern normal cell 
proliferation and homeostasis. In their 
landmark paper Hanahan and Weinberg 
described six essential alterations 
cellular physiology that most, if not all, 
cancers share: insensitivity to anti-growth 
signals, self-sufficiency in growth signals, 
limitless replicative potential, evasion 
of programmed cell death (apoptosis), 
sustained angiogenesis (blood vessel 
formation), and tissue invasion and 
metastasis (Hanahan and Weinberg, 
2000). These traits individually may apply 
to different cancers to different degrees. 
One additional characteristic that cancer 
cells have is the instability of their genomes, 
or their increased mutational capacity. 
This characteristic enables tumor cells to 
reach the six above-mentioned traits by 
mutating genes coding for components of 
the signalling pathways involved in these 
traits. If not for this characteristic, cancer 
would be a very rare disease because 
our genome maintenance and repair 
systems have a very high fidelity. It is 
possible to recapitulate these traits in in	
vitro experimental systems using normal 
human cells, these can be transformed 
into cancer cells by introduction of only a 
few genes (Hahn et al., 1999).
Mutated cancer genes generally come 
in three flavors; oncogenes, tumor-
suppressor genes, and stability genes. 
These mutations are best explained 
by analogies that Bert Vogelstein used 
(Vogelstein and Kinzler, 2004). A mutation 
in an oncogene is analogous to a stuck 
accelerator in an automobile; the car 
still moves forward even when the driver 
removes his foot from it. An example of 
such a gene is is Ras, activating mutations 
in this gene are found in approximately 
30% of human cancers, it provides 
the cell with an intrinsic growth signal 
(Duursma and Agami, 2003). A mutation 
in a tumor-suppressor gene is analogous 
to a dysfunctional brake in an automobile; 
the car doesn’t stop even when the driver 
attempts to engage it. The best known 
example of a tumor suppressor is p53, 
this is the most frequently mutated gene 
in cancer (Oren, 2003). The p53 gene 
encodes a protein whose function is to 
inhibit cell growth and stimulate cell death 
when induced by cellular stress. Another 
example relevant for this thesis is the 
tumor suppressor p27KIP1, this protein is 
an inhibitor of the cell cycle and is often 
expressed to lower levels in human 
cancers (Chu et al., 2008). Noteworthy 
is that inactivating mutations of p27 
are rarely observed in human cancer, 
other mechanisms, including microRNA 
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mediated downregulation are involved (le 
Sage et al., 2007). In the analogy to autos, 
stability genes represent the mechanics 
and a defective stability gene is akin to 
an inept mechanic. The breast cancer 
susceptibility gene BRCA1 is a well 
known example of this class of genes, it is 
involved in DNA repair (Gudmundsdottir 
and Ashworth, 2006). 
Outline of this thesis
Described above are some basic 
molecular principles in cancer biology. In 
my thesis I will describe several players 
in signalling pathways that are in some 
way connected to these basic principles 
of cancer. Sometimes this connection 
is not so clear, that is because in 
cancer research we often stumble upon 
interesting biological phenomena that 
provide a deeper insight into the inner 
workings of cells. Eventually, this greater 
understanding will hopefully lead to new 
insights to treatment of diseases, including 
cancer. In chapter 4 I have investigated 
the role of hTR, the RNA component of 
telomerase (an enzyme involved in the 
acquired capability of cancer cells to reach 
a limitless replicative potential) in the 
response to DNA damage. This response, 
in turn, is connected to the characteristic 
of cancer cells of genome instability, in this 
case through a reduced potential of cancer 
cells to respond to DNA damage (Kedde 
et al., 2006). The analysis of the function 
of Dead End 1, described in chapter 3 
(and reviewed in chapter 2 (Kedde and 
Agami, 2008)), may be important for our 
understanding of cancers deriving from 
the germ line but is quite likely more 
generally applicable (Kedde et al., 2007). 
This chapter also reveals a glimpse of 
a layer of gene regulation previously 
underappreciated; that is noncoding 
RNA regulation. In chapter 5 a novelty 
in such an RNA regulation mechanism 
is described, namely the targeting of a 
relatively new class of RNAs, microRNAs 
(miRNAs), to the coding region of the 
DNMT3b transcript (Duursma et al., 
2008). What all studies described in this 
thesis have in common is the regulation 
of cellular processes by noncoding RNA 
molecules, functions that just a decade 
ago would almost exclusively be ascribed 
to proteins. Therefore, I have tentatively 
dubbed these new playgrounds for RNA 
in this thesis. With the recently acquired 
deeper knowledge about our genome, it 
is beginning to be appreciated that RNA 
plays a major role in regulation of cellular 
processes, much bigger than previously 
anticipated (Mattick, 2007). 
I will give a short introduction on some 
relevant topics for this thesis below. The 
DNA damage response is closely related 
to cancer as said above, some background 
on this topic is relevant for chapter 4, where 
I describe a modulator of this response. 
This modulator is an RNA molecule that 
was identified about two decades ago, 
as a cofactor for the telomerase enzyme 
(Greider and Blackburn, 1987; Greider 
and Blackburn, 1989). For several years, 
this was one of the few examples of an 
RNA molecule having a regulatory role, it 
was thought to merely aid the telomerase 
enzyme in doing its job. The notion that 
only a few RNAs would act as cofactors 
for some specific enzymes stems from 
those and earlier times. That is why I have 
classified human telomerase RNA (hTR) 
as a “classical” RNA. The other chapters 
(chapters 2, 3, and 5) in this thesis are 
related to miRNAs. These molecules 
were identified in the early nineties, but 
they came only very recently under great 
attention when it became clear that this 
is a large class of new genes, capable 
of regulating a big part of our genome. 
I will introduce miRNAs below, and they 
will be further discussed in chapter 2, 
in the context of Dead end, a protein 
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we identified as a modulator of certain 
miRNAs. 
DNA Damage, the ATR side of 
the story
Our genome is under constant attack 
by ultraviolet (UV) and ionizing radiation 
(IR), chemicals from our enviroment such 
as from food and cigarette smoke, and 
from metabolites produced by our own 




. Such DNA damage 
is detrimental to us, therefore elaborate 
mechanisms have evolved to deal with 
this damage. Understanding the DNA 
damage response is very important for 
cancer biology because DNA damage 
not only causes cancer by introducing 
mutations in our genes, it is also used 
to treat cancer in the form of irradiation 
and many chemotherapeutics, and it 
is the cause of many side effects of 
treatments (Kastan and Bartek, 2004). 
DNA damage triggers processes in the 
cell that lead either to damage repair and 
safe resumption of the cellular life cycle, 
or to programmed cell death (apoptosis), 
depending on the amount and type of 
damage. There are several types of DNA 
damage, and different protein complexes 
exist for recognition and repair of these 
lesions. 
The DNA damage response in cells is 
organised by a network of pathways 
that contain sensor proteins, mediators, 
transducers, and effectors (Zhou and 
Elledge, 2000). Central to nearly all DNA 
damage responses are the transducer 
phospho-inositide kinase-related protein 
kinases ATM (ataxia telangectasia 
mutated) and ATR (ATM-Rad3-related). 
In response to DNA damage, these 
kinases are immediately activated by 
interactions with the sensor complexes 
and the damaged DNA and phosphorylate 
downstream targets that eventually 
orchestrate the response of the cells. This 
can be halting the cell cycle and activating 
repair proteins, permanently stopping the 
cell cycle (also referred to as senescence) 
if the damage is more extensive, or 
activating the apoptosis pathway, thereby 
killing the cell (Bartek and Lukas, 2007; 
Zhou and Elledge, 2000). ATM is mainly 
activated in response to double stranded 
DNA breaks, the most toxic type of 
damage to cells, if unresolved, the cell will 
die. ATR responds primarily to replication 
stress and single stranded DNA (ssDNA) 
gaps, it also responds to double stranded 
DNA breaks albeit with slower kinetics. 
ATR and its binding partner ATRIP bind 
to replication protein A (RPA), which 
coats ssDNA as soon as it is formed 
by a replication block, resolvement of 
ssDNA breaks or other damage (Byun 
et al., 2005; Cortez et al., 2001; Zou 
and Elledge, 2003). Other proteins, like 
the Rad17 and 9-1-1 complex are also 
loaded on the DNA which give rise to a 
docking platform for DNA repair proteins, 
mediators and transducers (Harper and 
Elledge, 2007). This complex further 
interacts with a protein called TopBP1, 
which then fully activates ATR kinase 
activity (Kumagai et al., 2006; Mordes 
et al., 2008). At this point, a myriad of 
proteins is recruited to the site of damage 
and a so-called DNA damage focus 
forms, it is thought that these foci function 
as a surrogate for DNA damage recruiting 
proteins that orchestrate the response to 
solve the problem. An important player in 
this process is the histone variant H2AX, 
which becomes phosphorylated on serine 
residue 139 (then dubbed γH2AX) by 
ATM, ATR, and DNA PK (Rogakou et al., 
1998). Recently, DNA damage foci have 
have been detected in early stage tumors, 
and linked to replication stress induced 
by activation of oncogenes (Bartkova et 
al., 2005; Di Micco et al., 2006; Gorgoulis 
et al., 2005). These data show that DNA 
damage is an early event in tumorigenesis, 
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Figure 1. The ATR mediated DNA damage response. Multiple DNA damage insults 
activate ATR, such as replication stress, ssDNA gaps and UV-induced adducts. Sensors (the 
9-1-1 complex and Rad17) are then recruited to the site of damage and ATR is activated. A 
DNA damage focus forms by spreading of H2AX phosphorylation and association of the MRN 
complexes and proteins such as 53BP1. Chk1 and p53 are amongst ATRs most important targets, 
they are activated by phosphorylation, TopBP1 is required for activation of Chk1, whereas p53 is 
directly activated by the ATR-atrip dimer. Chk1 immediately halts the cell cycle by phosphorylating 
the Cdc25 proteins, thereby targeting them for degradation, it can also phosphorylate p53. P53 
activates transcription of genes that sustain the cell cycle arrest (such as p21) and activate DNA 
repair or apoptosis. See text for details.






































however, to become cancerous, cells have 
additional safeguards to overcome, such 
as senescence, which was shown to be a 
barrier to tumorigenesis in	vivo	 (Braig et 
al., 2005; Chen et al., 2005; Collado et al., 
2005; Michaloglou et al., 2005; Serrano et 
al., 1997).
If we now go more downstream in the 
DNA damage response, towards the 
effectors/transducers, we find proteins that 
regulate DNA repair, senscence, splicing, 
chromatin remodelling, apoptosis, and, 
important for this thesis, the cell cycle. 
This is the reproductive cycle of cells, 
from replicating their DNA, followed 
by the division of the nuclei and the 
partitioning of the cytoplasm to yield two 
daughter cells. In the G1 phase (gap1), 
cells make decisions regarding whether 
to differentiate, self-renew, or die, on 
the bases of complex signals from their 
surroundings and from within the cells (see 
below). In S phase (synthesis of DNA), 
cells copy their genomes in order to divide 
it between their daughters in M phase 
(for mitosis), but not before everything is 
checked in G2 phase. Regulation of the 
cell cycle is orchestrated by oscillations 
in the activities of cyclin dependent 
kinases (Cdks). Inhibition of Cdks is 
achieved by tyrosine phosphorylations 
by proteins such as Wee1 and binding of 
Cdk inhibitor proteins, such as p21 and 
p27KIP1, whereas activation is achieved 
by cyclins and de-phosphorylation by 
proteins such as Cdc25. Chk1 is an 
important ATR downstream target kinase 
that is involved in directly halting the cell 
cycle through stimulating the degradation 
of Cdc25 proteins (Liu et al., 2000; 
Mailand et al., 2000; Molinari et al., 2000; 
Sorensen et al., 2003). ATR activates 
Chk1 by phosphorylation on two serine 
residues (S317 and S345) (Zhao and 
Piwnica-Worms, 2001). Chk1, like ATR, 
is an essential gene, disruption causes 
embryonic lethality in mice and loss of 
viability of knockout cells, this shows 
that the ATR pathway is required for 
normal replication (Brown and Baltimore, 
2003; Takai et al., 2000). Chk1 also 
phosphorylates, and thereby activates, the 
p53 tumor suppressor, which is involved 
in the maintenance of the cell cycle arrest 
(Shieh et al., 2000).
The p53 protein is a direct target of ATR 
as well, ATR phosphorylates serine 15 
(Tibbetts et al., 1999). The p53 protein sits 
at the junction of an extremely complex 
network of cellular pathways responding to 
inputs such as oncogene activation, DNA 
damage, mitotic impairment or oxidative 
stress. In response to these stresses 
p53 is activated in a specific manner by 
post-translational modifications, these 
stabilize the protein, leading to greater 
concentrations, as well as enhance 
its DNA binding capacity, activating its 
transcriptional activity. It then orchestrates 
diverse outputs such as DNA repair, cell 
cycle arrest, senescence, or apoptosis. 
A few examples of p53 target genes are 
GADD45a, which is involved in DNA repair, 
p21, that initiates cell cycle arrest, and 
BAX, is a factor that stimulates apoptosis 
(Riley et al., 2008). P53 is mutated in 
approximately half of all cancers, in many 
other cancers components of the p53 
pathway are mutated, underscoring the 
vital importance of this protein (Oren, 
2003).
The `classical` RNA world, the 
tale of hTR
The distinction between `new` and 
`classical` RNAs is just made here to 
emphasize the difference in thinking 
about RNA before the early nineties 
and nowadays, I will explain this here. 
Our thinking about gene regulation and 
organization has been shaped in large 
part by the description of the lac operon 
in bacteria by Jacob and Monod in 1961 
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(Jacob and Monod, 1961). Their model 
of gene structure and regulation is highly 
linear, one stretch of DNA codes for only 
one function, either regulatory or protein 
coding. Although they already suggested 
that RNA could also have a regulatory 
role as the repressor of the lac operon, 
this factor was later found to be a protein. 
Potential regulatory roles for RNA were 
dismissed for years to come and the 
gene models remained protein-centric. 
After the discovery of splicing (genes are 
interrupted, rather than coding for protein 
from beginning to end) in 1977, the intronic 
RNAs were considered to be unimportant, 
merely byproducts of the splicing process 
(Berget et al., 1977; Chow et al., 1977). It 
was, however, appreciated that RNA plays 
an important role in the translation process 
of mRNA to proteins. The ribosome was 
found to consist, in large part, of RNA, the 
translation process depends on transfer-
RNAs, and for splicing, several snRNAs 
were identified that guide the process. 
The discovery in the 1980’s by Thomas 
Cech, that non protein coding RNAs can 
also have catalytic functions (rybozymes) 
showed that RNA is a lot more versatile 
than previously thought and started the 
debate whether an “RNA world” is the 
initiator of cellular life (Zaug and Cech, 
1986). 
Only about one percent of our genome 
codes for proteins, does that make the 
rest of the genome “junk” DNA? In the 
advent of the human genome project (with 
the first draft published in the year 2000) 
and the development of better techniques 
to analyse the expression of the genome, 
scientists found that over 90% of our 
genome is transcribed (Cawley et al., 
2004; Cheng et al., 2005; Kapranov et 
al., 2007a). These and other studies 
have shown that there are hundrends 
of thousands of ncRNAs expressed in 
cells, and in the last few years several of 
those have been shown to have specific 
regulatory capacities (Mattick, 2007; 
Prasanth and Spector, 2007). Many of 
the ncRNAs are conserved, have specific 
spatial and temporal expression patterns 
and several are involved in disease 
(Amaral et al., 2008; Mercer et al., 2008; 
Perez et al., 2008). Thousands of proteins 
are capable of binding RNA but for only 
a few, some of their targets are known. 
Together with the discoveries of miRNAs 
(see below) and several other small RNA 
species, these data suggest that the roles 
of ncRNAs have been underestimated 
and we are just scratching the surface of 
this `new` RNA world.
Human telomerase RNA (hTR) was 
identified in 1987 as the essential cofactor 
for the telomerase protein, providing the 
template to elongate telomeres (Greider 
and Blackburn, 1987; Greider and 
Blackburn, 1989). The only functionally 
important part of the molecule was 
considered to be the template region 
(6 nucleotides of the 451 in total) and 
the rest of the molecule was thought to 
merely aid in the processing and binding 
to the telomerase protein, this is why I 
classify it as a`classical` RNA (Chen et 
al., 2000; Feng et al., 1995). In chapter 
4, however, I describe the identification of 
an unexpected,  telomerase independent, 
role of hTR in DNA damage regulation. 
Telomerase is the complex of hTR with 
the telomerase enzyme (hTERT) and a 
protein called dyskerin, that can extend the 
ends of chromosomes, called telomeres 
(Cohen et al., 2007). This complex is 
only active in germ cells, certain stem 
cells, and is re-activated in most (>85%) 
cancers (Kim et al., 1994). Telomeres 
are specialised structures consisting of 
telomeric DNA repeats  (5’-TTAGGG-3’) 
and associated proteins at the ends of 
the chromosomes that protect them from 
activating a DNA damage response and 
from the loss of genomic information. 
Because the DNA in higher eukaryotes 
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is linear, normal cells that don’t express 
telomerase activity, lose a bit of the end of 
their chromosomes each cell division. This 
is due to the inability of DNA polymerases 
to synthesize the ends of linear stretches 
of DNA (they need an RNA primer and 
only work in one direction). Obviously, this 
problem, also called the end replication 
problem, will eventually lead to loss of 
genetic material, and such a dsDNA 
`break` would elicit a DNA damage 
response (Longhese, 2008). In fact, this 
is the reason that cells have a limited 
replicative lifespan, they reach the so-
called Hayflick limit after a certain number 
of doublings, and go into replicative 
senescence (permanent withdrawal from 
the replicative cycle) (Harley et al., 1990; 
Hayflick and Moorhead, 1961). This is a 
barrier that cancer cells have to overcome 
to reach their limitless replicative potential 
(see above). To overcome this barrier 
cancer cells either increase hTERT and 
hTR levels or use a recombination based 
way of extending telomeric repeats (ALT, 
for Alternative Lengthening of Telomeres) 
(Bryan et al., 1997; Bryan et al., 1995; 
Kim et al., 1994). 
hTR is a ubiquitously expressed RNA, 
whereas hTERT is only expressed in 
stem cells and cancer cells, this suggests 
that hTR may have a seperable role from 
telomere lengthening. This was also 
suspected from in vitro data from cell 
lines, mouse models and in fact, even 
from human tumor samples but never 
investigated. It was shown that hTR may 
also play a role in initiation of tumorigenicity 
for it was shown that its upregulation is an 
early event, even in mice where telomere 
length is not an issue at this stage, 
because telomeres are suficiently long 
(Blasco et al., 1996; Broccoli et al., 1996). 
Very convincing data for this point comes 
from several studies that investigated 
human tumors and show that hTR, and 
not hTERT levels or not even telomerase 
activity is correlated to tumor stage, 
these studies include cervical carcinoma, 
lung cancer, leukemia, head and neck 
cancer, renal cell carcinoma, esophageal 
adenocarcinoma, childhood neuroblastic 
tumors, as well as breast carcinomas 
and several other cancers (Brown et al., 
1997; Cao et al., 2008; Dome et al., 2005; 
Maitra et al., 1999; Morales et al., 1998; 
Rushing et al., 1997; Soder et al., 1997; 
Yashima et al., 1997; Yashima et al., 
1998). In chapter 4 I will describe that we 
have shown that increased levels of hTR, 
as found in these tumors, can dampen 
the ATR mediated DNA damage response 
and thereby fuel genomic instability as 
shown by the induction of fragile sites. 
hTR levels are controlled by several, not 
fully understood, transcriptional and post-
transcriptional mechanisms (Cairney and 
Keith, 2008).  We have shown that also 
ATR activation by UV irradiation can cause 
an upregulation of hTR that provides a 
negative feedbackloop to ATR (Kedde et 
al., 2006). It is conceivable that a similar 
mechanism upregulates hTR in response 
to replication stress in early lesions to 
counteract ATR activity, however, this 
remains to be tested. 
The ̀new` RNA world, microRNAs 
lead the way
Only very recently a whole new world 
of RNAs has been revealed, starting at 
the characterization of the lin-4 locus, 
which produces small, noncoding RNA, 
regulating developmental timing in C. 
elegans (Lee et al., 1993). This small 
RNA was found to contain complementary 
sequences to the 3’ untranslated region 
(UTR) of the lin-14 mRNA and inhibit its 
translation by an RNA-RNA interaction. 
Several years later Fire, Mello and 
coworkers found that dsRNAs, when fed 
to elegans worms, are cleaved into small 
~22nt RNAs that trigger gene silencing 
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Figure 2. The miRNA pathway. Most miRNAs are transcribed by RNA polymerase II as long 
RNAs (Pri-miRNAs) that are converted to ~70 nt long pre-miRNAs by Drosha and Pasha (Lee 
et al., 2003). Mirtrons are a new class of miRNAs that can bypass this step, they are generated 
through splicing (Ruby et al., 2007). The pre-miRNAs are then exported to the cytoplasm 
by Exportin 5, converted to ~22 nt mature miRNAs by Dicer and one strand of the duplex is 
incorporated into the RNA induced silencing complex (RISC)(Gregory et al., 2005; Maniataki 
and Mourelatos, 2005). In animals, miRNAs utilize a seed sequence at their 5’ end (nt 2-8) to 
associate with 3’UTR regions of mRNAs to suppress gene expression by inhibiting translation 
that occasionally is associated with mRNA decay (Bagga et al., 2005; Lim et al., 2005; Pillai et 
al., 2005). In Chapter 5, we show that in some cases miRNAs can also bind to targets in their 
coding region and repress their expression. Repressed mRNAs, miRNAs, and most proteins 
constituting the miRNA-RISC complex (miRNP) are enriched in cytoplasmic processing bodies 
called P-bodies (Liu et al., 2005). Some RNA binding proteins (RBPs), like Dead end, can inhibit 



























of complementary endogenous targets, 
a process they dubbed RNA interference 
(RNAi) (Fire et al., 1998). The existence 
of similar interference processes in all 
higher eukaryotes, including humans, 
was identified soon and RNAi started to 
be generally used as a tool to inhibit gene 
expression and thereby systematically 
investigate the genome (Brummelkamp 
and Bernards, 2003; Brummelkamp et 
al., 2002). From zebrafish to man, these 
systems were exploited beacause of the 
ease of using dsRNA (for Drosophila and 
C. elegans), or short hairpin or siRNAs 
(human and mouse cells) to inhibit gene 
expression. However, scientists knew 
that a similar mechanism must be used 
for an endogenous pathway of gene 
silencing. This was becoming apparent 
when scores of miRNAs were discovered 
(~1000 are predicted) that are encoded in 
genes in our genome and miRNAs were 
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predicted to regulate over a third of our 
genome (Aravin and Tuschl, 2005; Lagos-    
Quintana et al., 2001; Lagos-Quintana 
et al., 2003; Lagos-Quintana et al., 
2002; Lau et al., 2001; Lee and Ambros, 
2001; Lewis et al., 2005). MiRNAs have   
now been shown to paticipate in a wide 
variety of cellular processes and the 
vast majority of miRNAs show tissue or 
developmental stage-specific expression 
(Lagos-Quintana et al., 2002; Lim et al., 
2005; Wienholds et al., 2005). Importantly, 
aberrant expression or activity of miRNAs 
can lead to disease, such as cancer 
(Filipowicz et al., 2008; Kloosterman and 
Plasterk, 2006).
A typical literature search for miRNA 
targets now yields approximately 1000 
results, starting at the first identification 
by Lee and Ambros (Lee and Ambros, 
2001). More and more miRNAs and 
miRNA targets are being discovered. 
Recently a whole new class of conserved 
miRNAs were discovered in introns, 
dubbed mirtrons, that bypass processing 
by Drosha (Berezikov et al., 2007; Ruby 
et al., 2007). Adding to this complexity of 
post transcriptional regulation of mRNAs 
by miRNAs are diverse ways of regulation 
of miRNAs themselves by transcription, 
editing, processing, and subcellular 
localisation as well as modulation of 
miRNA function by proteins such as HuR 
and Dead end 1  (also described in the next 
chapter and chapter 3)(Bhattacharyya et 
al., 2006; Filipowicz et al., 2008; Kedde 
and Agami, 2008; Kedde et al., 2007). 
Intriguingly, it has now been reported that 
in response to proliferation cues, certain 
cells decrease their 3’UTR length by 
switching to alternatve poly adenylation 
sites in order to avoid miRNA regulation 
(Sandberg et al., 2008).
Not long after the discovery of miRNAs 
our protein centered view of the genome 
was challenged by the findings that 
transcription is widespread and highly 
interleaved (Kapranov et al., 2007b; 
Mattick, 2007; Prasanth and Spector, 
2007). In these findings lies a whole new 
RNA world, waiting to be discovered. 
The notion that functional ncRNAs 
have a huge size range, from ~22bp for 
miRNAs to ~18kb for XIST (X-inactive 
specific transcript) and ~108kb for AIR 
(antisense IGF2R RNA) and that ncRNAs 
far outnumber protein coding RNAs 
highlight their importance. The fact that 
ncRNAs are already being identified as 
diagnostic markers for cancer and other 
diseases shows that there is not just very 
interesting biology to learn here but also 
potential benefit for patients (Amaral et 
al., 2008; Calin et al., 2007; Kloosterman 
and Plasterk, 2006; Kumar et al., 2007; 
Perez et al., 2008). In light of this, miRNA 
silencing by LNA oligonucleotides has 
already been reported in non-human 
primates, paving the way for miRNA 
targeting therapeutics in the future (Elmen 
et al., 2008).
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Interplay between microRNAs and RNA-binding 
proteins determines developmental processes
Germ cells reveal a complex RNA world




One of the first steps occurring in a 
developing embryo is the formation of 
the germ line, a necessity for species 
continuity. To remain totipotent (capable 
to form an entire organism), the germ 
cells have to preserve the naive state of 
their genomes and inhibit the activation 
of somatic genes. The mechanisms 
behind the specification, migration and 
further development of germ cells are 
being elucidated in various organisms 
and appear to be remarkably similar.3,4 
The understanding of the molecular 
mechanisms governing germ cell 
development is likely to provide insights 
to genome protection, to analogous cell 
differentiation  processes in somatic stem 
cells, and to germ cell diseases, such as 
testicular and ovarian cancers.
The so-called primordial germ cells (PGCs) 
are set apart from somatic cells early in 
development (in some organisms PGCs 
are the first cell lineage to be determined) 
at a location distinct from the gonad, and 
start migrating toward the future gonad. 
After the PGCs arrive in the gonad they 
start proliferating and differentiate into 
germ-line stem cells capable of forming 
the gametes. The migration of this small 
group of PGCs (40–45 in mice and 
zebrafish) is a remarkable feat of these 
cells, requiring guidance by attractive 
and repulsive cues from somatic tissues.5 
The involved chemokines and receptors, 
such as Sdf-1 and Cxcr4, are conserved 
throughout evolution.6-9 In zebrafish, 
the PGCs are specified in 4 different 
locations in the developing embryo, then 
they follow six different migration steps 
and practically all arrive in the gonad.5 
The RNA-binding protein (RBP) Dead 
end (Dnd1) is essential for PGC motility 
in zebrafish, as cells depleted of Dnd1 
do not polarize, form psuedopodia, and 
Interplay between microRNAs and RNA-binding proteins 
determines developmental processes
Germ cells reveal a complex RNA world
Martijn Kedde and Reuven Agami
MicroRNAs (miRNAs) are genes involved in normal development and cancer. They 
inhibit gene expression by associating with 3’-Untranslated regions (3’UTRs) of 
messenger RNAs (mRNAs), and are thought to regulate a large proportion of 
protein coding genes. However, it is becoming apparent that miRNA activity is not 
necessarily always determined by its expression in the cell. MiRNA activity can be 
affected by RNA-binding proteins (RBPs). For example, the RNA-binding protein 
HuR associates with the 3’UTR of the CAT1 mRNA after stress, counteracting the 
effect of miR-122.1 Second, we found that the expression of an RNA binding protein 
called Dead end (Dnd1) prohibits the function of several miRNAs by blocking the 
accessibility of target mRNAs.2 Dnd1 function is essential for proper development 
of primordial germ cells (PGCs) in zebrafish and mammals, indicating a crucial 
role for RBP/miRNA interplay on 3’UTRs of mRNAs in developmental decisions. In 
this review we discuss the interplay between RBPs and miRNAs in the context of 
germ cells and review current observations implicating RBPs in miRNA function.
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subsequently die by apoptosis.10 The 
requirement of Dnd1 for PGC survival 
appears to be conserved. Mice with a 
naturally occurring truncation mutation in 
the Dnd1	gene (the Ter mutation) lose most 
PGCs. However, still few Dnd1-mutant 
PGCs end up in the gonad, showing 
that the migration capacity of PGCs, in 
general, is not affected.11 In most cases, 
the control of PGCs survival is intimately 
linked with migration, because PGCs that 
end up in the wrong place are usually 
quickly eliminated.12 In some cases 
though, PGCs end up in extragonadal 
sites and escape elimination. It is thought 
that these cells can give rise to pediatric 
germ-line tumors.13,14 The identification 
of Dnd1 targets and their function would 
therefore be important to determine the 
molecular mechanisms involved in cell 
migration, at least in zebrafish, germ cell 
survival, and germ-line cancers.
The Germ Plasm: RNA 
Regulation Determines Germ 
Cell Fate
One of the most distinctive features of 
PGCs is the appearance of electron-dense 
structures  associated with mitochondria 
that contain RNA and proteins called 
either germ plasm, nuage or chromatoid 
bodies.4,15 In mammals, PGCs do not 
have an apparent germ plasm, rather; a 
mammalian counterpart of germ plasm with 
a similar overall structure and homologous 
components is present in mouse haploid 
male germ cells. Nonetheless, germ plasm 
components, such as Dnd1 and Vasa, are 
required for proper PGC function also in 
mammals.11,16,17
As shown in zebrafish embryos by 
transplantation experiments, the germ 
plasm itself is indispensable for germ 
cell establishment.18 It appears that germ 
plasm is a place in the cytoplasm where 
certain mRNA species are stored and 
repressed, awaiting activating signals 
for expression. Studies  from a variety of 
different organisms have indicated that 
the primary role of germ plasm is the 
handling of RNA. This includes storage 
and regulation of mRNA translation as 
well as regulation of some non-coding 
RNAs. Many different RBPs, such as 
Vasa, Dnd1, Argonaute, PIWI, Tudor, 
and SM, are localized to the germ plasm, 
together with several RNAs, including the 
nanos, tdrd7, and dead	end	mRNAs and 
also micro- and Piwi-associated-small 
RNAs.4,10,15,19-22
Why do germ cells rely so much on RNA for 
their survival? Seydoux and Braun have 
put forward the interesting hypothesis that 
germ cells rely on RNA-based program 
of posttranscriptional regulation to keep 
their genome in a ‘totipotent’ state.4,19 
This stems from the notion that germ 
cell nuclei present extensive chromatin 
remodeling activity to establish unique 
chromatin while transcription is widely 
repressed.23 Germ plasm would be the 
physical manifestation of this RNA-
based program. Dnd1, a protein that is 
localized to the germ plasm, is associated 
with actively translated nanos, and tdrd7	
mRNAs, that are also located in the germ 
plasm.2,10,21 These data suggest that germ 
plasm is a site of active translation.
An alternative explanation may be that 
the translationally active Dnd1-mRNA 
complexes are localized elsewhere, where 
they are inaccessible to translational 
repressors (miRNPs, also shown to be in 
the germ plasm, see below).2 However, 
these locations have not been detected 
thus far. As our current knowledge solely 
depends on in situ mRNA hybridization 
experiments and RNA reporters coding 
for fluorescent proteins carrying a 3’UTR 
of genes of interest, colocalisation 
of endogenous Dnd1 protein with 




MicroRNAs, the Germ Cell 
Perspective
It has been recently suggested that the 
cytoplasmic processing body (P-body), the 
site where repression of mRNA translation 
is thought to occur, might be the somatic 
counterpart of the germ plasm.22 These 
structures are similar and share several 
constituents such as translationally-
repressed mRNAs, factors involved in 
inhibition of translation, miRNAs, and 
most proteins constituting the miRNA-
RISC complex (miRNP, see below). In 
line with this, cytoplasmic P-bodies lack 
ribosomes and translation initiation factors 
and are known to be sites of translational 
repression and mRNA decay.25,26
MicroRNAs are ~22-nucleotides (nt) 
RNAs widely expressed in metazoans.27,28 
These small RNAs are negative regulators 
of gene expression capable of defining 
and altering cell fate. Around 500–1000 
miRNAs are estimated to be present 
in the mammalian genome, and a large 
proportion of human protein-coding genes 
are thought to be under the regulation of 
one or more miRNAs.29,30 Analogous to 
transcription factors, miRNAs regulate 
mRNAs in a combinatorial fashion and 
single miRNAs can repress the translation 
of many mRNAs. A growing body of 
evidence suggests that miRNAs participate 
in the regulation of a large variety of cellular 
processes and that the vast majority of 
miRNAs show tissue or developmental 
stage specific expression.31-33 Importantly, 
aberrant expression or activity of miRNAs 
can lead to disease.28,34,35 Most miRNAs 
are transcribed by RNA polymerase 
II as long RNAs that are converted to 
~70 nt long pre-miRNAs by Drosha.36 
The pre-miRNAs are then exported to 
the cytoplasm by Exportin 5, converted 
to ~22 nt mature miRNAs by Dicer and 
one strand of the duplex is incorporated 
into the RNA induced silencing complex 
(RISC).37,38 In animals, miRNAs utilize 
a seed sequence at their 5’ end (nt 
2–8) to associate with 3’UTR regions of 
mRNAs to suppress gene expression 
by inhibiting translation that occasionally 
is associated with mRNA decay.26,32,39 
Translation is thought to be inhibited 
at the initiation step, by competition of 
Ago proteins with  translation initiation 
factors eIF6 and eIF4e.40-42 Last, MVH 
(Mouse Vasa Homolog) was found to 
interact with Dicer in germ plasm and 
therefore has been proposed to be the 
germ cell-specific helicase for the miRNA 
pathway.22 Some critical components of 
the miRNA pathway, such as Dicer, and 
likely also some miRNAs, are essential for 
germ cell maintenance and put miRNAs 
forward as important players in germ cell 
biology.24,25,43-46
The fact that miRNAs are present in 
germ plasm together with most proteins 
constituting the miRNA-RISC complex, 
suggests germ plasm being a repressive 
hub for mRNAs. However, most peculiarly, 
it was recently documented that two 
miRNA targets of miR-430 in zebrafish are 
not repressed in PGCs, while miR-430 is 
present.24 MiR-430 is a family of several 
miRNAs that are required for clearance 
of maternal transcripts in the developing 
embryo.4,47 Mishima and colleagues have 
suggested that specific regions in the 
3’UTR of the nanos1	 and tdrd7	 genes 
counteract miRNA-mediated repression 
in the germ-line cells. Therefore, we 
hypothesized that germ cells contain 
specific factors that bind mRNAs and 
counteract miRNA function. Using a 
genetic screening approach, we identified 
the RNA-binding protein Dead end as 
a factor involved in this phenomenon in 
both zebrafish PGCs and human germ 
cells.2 By binding to U-rich mRNA regions 
(URRs), Dnd1 suppressed miR-430 
function, at least in part through blocking 
miRNA accessibility.
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The human microRNA homologues of 
miR-430 in zebrafish are miR-373, -372, 
-520, -302 and -93 (here termed miR-373 
family). We have shown that the miR-
373 family acts as potential oncogenes 
in human germ cells, presumably by 
facilitating rapid proliferation.48 Moreover, 
expression of this miRNA family is 
associated with enhanced cellular 
migration, invasion and metastasis.49 
Since inhibition of Dnd1 expression in 
human testicular germ cell tumor cell 
lines resulted in the loss of miR-373 
family targets, it is possible that a balance 
between miR-373 family function and 
Dnd1 exists in germ cells and increased 
level of miR-373 family overcomes Dnd1 
function, resulting in target inhibition and 
accelerated proliferation. This notion 
is supported by findings made in mice. 
A truncating mutation in Dnd1 in the 
background of the 129-mouse strain (Ter 
mice), but not other mouse strains, results 
in testicular tumor formation. These 
tumors arise from the few germ cells that 
able to survive and further develop in the 
absence of Dnd1.11 Interestingly, miRNA-
107 was identified as one susceptibility 
gene in the 129 Ter strain that can allow 
germ cell tumor growth in the absence of 
Dnd1.50 This may point for a connection 
between Dnd1, miRNAs and testicular 
germ cell cancer. However, no mutations 
were observed in Dnd1 in human testicular 
germ cell tumors.51 Further experiments 
are required to examine the role of Dnd1 
in other tumor types such as brain tumors, 
where Dnd1 is occasionally expressed.
From these data, it is clear that miRNAs 
and Dnd1 are closely tied together in germ 
cells. However, the extent of this interplay 
is yet to be determined. For instance, we 
do not know how many miRNA targets 
Dnd1 regulates and also the exact impact 
of germ cell miRNAs on gene expression 
is not clear. On top of that, we do not know 
whether the sole function of Dnd1 is the 
repression of miRNA activity or perhaps 
there are other functions that have been 
concealed in the experiments thus far. It 
will be interesting to determine in the near 
future whether blocking miRNA activity 
is the most important function of Dnd1 
during development of germ cells.
piRNAs, Germ Plasm Reveals 
more Essential RNAs
Another novel class of small RNAs 
exclusively expressed in the germline was 
recently identified in several organisms 
including Drosophila, zebrafish, and 
mouse.52 These are 24–30 nucleotide 
RNAs that are generated by a Dicer 
independent mechanism and interact 
with the Piwi class of Argonaute proteins, 
therefore named piRNAs.52-54 The Piwi 
protein was identified a decade ago 
in Drosophila as a germ plasm factor 
essential for the regulation of germline 
stem cells.55 In the past two years, several 
independent laboratories identified 
piRNAs to be crucial for germ line 
development of several organisms.53,54,56-61 
In general, piRNAs are thought to silence 
selfish DNA elements and maintain germ 
line DNA integrity.How exactly piRNAs are 
generated is not completely understood. 
It was shown that in Drosophila ovaries, 
most piRNAs appear to be derived from 
a discrete number of sites enriched 
in transposon sequences, the most 
abundant piRNAs derive from the 
antisense strand of retrotransposons.62,63 
Piwi and Aubergine were shown to bind 
piRNAs that are mostly antisense to 
transposons, whereas Ago3 appears to 
bind predominantly sense piRNAs, these 
proteins can cleave their target RNAs. A 
‘ping-pong’ model for piRNA production 
was proposed where sense and antisense 
piRNA populations are amplified in a loop 
wherein each piRNA-directed cleavage 
event generates the 5’ end of a new 
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piRNA.62,63 However, what determines their 
specific production in germ cells awaits 
further investigation. Moreover, whether 
and how they control gene transcription, 
translation, and genome organization is 
not well understood.
One interesting phenotype  observed 
in flies and mice that are mutated in the 
piRNA pathway is the emergence of 
DNA damage.64-66 This phenotype can 
only in part be explained by activation 
of transposons in the mouse and fly 
genomes. Several studies have indicated 
that there is no evidence of transposon 
activation when DNA damage is detected 
after piRNA depletion.52 Also, in mice 
there is less evidence that piRNAs target 
transposons directly. Is there a direct role 
for piRNAs in DNA repair or suppression 
of DNA damage pathways? This is an 
intriguing possibility. It was previously 
shown that RNA may function to regulate 
the activity of checkpoint proteins. For 
example, in human cells, the telomerase 
template RNA (hTR), can suppress the 
ATR kinase.67
Can Dnd1 also affect the piRNA pathway? 
Thusfar, we have not identified piRNAs 
as targets of Dnd1, but the link between 
piRNAs and the miRNA pathway, and their 
presence in germ plasm may suggest 
that these pathways influence each other. 
Germ cells that lack Dicer, which is crucial 
for the generation of miRNAs, develop 
normally, whereas Dnd1-depleted germ 
cells die.10,68 Mutations in the piRNA 
pathway, as Dnd1 depletion, causes 
germ cells to go into apoptosis, perhaps 
indicating a connection between the two. 
It remains to be seen whether Dnd1 and 
piRNAs functionally interact.
Emerging Modes of miRNA 
Regulation
The interplay between Dnd1 and 
miRNAs is one example of modulation 
of gene expression by RNA-binding 
proteins (RBPs). Other groups have also 
recently found RBPs to modulate miRNA 
activity.1,69-71 Two of these groups showed 
that miRNA-repressed mRNAs can be 
relieved from repression by synaptic 
stimulation of neuronal cells.69,70 When 
treated with BDNF, cultured rat neurons 
partially relieve Limk1 mRNA repression 
by miRNA-134.70 The mechanism of 
miRNA derepression in this system thus far 
remains unknown. Ashraf and colleagues 
showed that external stimulation of 
Drosophila olfactory neurons induces 
degradation of the Armitage protein, which 
is required for miRNP assembly.69 As a 
result, the translation of the protein kinase 
CaMKII mRNA, which is controlled by 
miRNAs, is enhanced. The fact that many 
RBPs, including Dnd1, are specifically 
expressed in brain suggests that miRNA 
reversibility is a more general mode of 
regulation.11,72 In light of these studies, 
it is conceivable that also Dnd1 plays a 
role in brain function, although specific 
brain defects have not been observed in 
Ter mice.11,72 To this end, it is also worth 
noting that inactivation of Dnd1 in mice 
leads to partial embryonic lethality, this 
is likely due to a role of Dnd1 in some 
critical, yet unknown, organ systems of 
the developing embryo.72
The group of Witold Filipowicz showed 
that HuR (ELAV1), an AU-rich element 
(ARE) binding protein, relieves CAT-
1 mRNA from miR-122-mediated 
repression, a process that involves 
binding of HuR to the 3’-UTR of CAT-1 
mRNA.1 The CAT-1 mRNA localizes to P-
bodies in a human hepatocarcinoma cell 
line in a miRNA-122 dependent manner. 
Upon stress, the CAT-1 mRNA relocalizes 
from P-bodies to the cytoplasm, where it 
associates with polysomes and becomes 
translationally active. This stress-induced 
effect is dependent on the translocation of 
HuR from the nucleus to the cytoplasm. 
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The mechanisms underlying HuR 
translocation are still poorly understood. 
Also, it is unknown whether HuR binding 
promotes the dissociation of miRNPs from 
the target mRNA, as Dnd1 appears to do, 
or just prevents them from repressing 
their targets. Whether Dnd1 also shuttles 
mRNA targets from P-bodies or germ 
plasm to active translation sites in the 
cytoplasm, is yet to be investigated. 
However, as Dnd1 in the systems we 
studied is localized in the germ plasm, 
apparently together with at least one of 
its targets, nanos	 RNA, it seems likely 
that Dnd1 does not translocate its targets 
from these bodies. It is worth to note that 
mouse Dnd1 appears to be either nuclear, 
or cytosolic, depending on the cell type.72 
We also reported significant amounts of 
the Dnd1 protein in the nucleus, when 
overexpressed in both MCF7 and HEK293 
cells.2 Whether this is an overexpression 
artifact, or reflects subcellular shuttling of 
Dnd1, remains to be investigated.
Other types of regulation of the miRNA 
pathway have also been observed. For 
instance, two studies showed recently 
that certain miRNAs, such as let-7 and 
miR-138, are not efficiently processed in 
all tissues and cell types in the mouse, 
whereas their precursors are present 
in these tissues.73,74 Interestingly, the 
group of Scott Hammond present data 
supporting a role for such mechanisms 
of miRNA-downregulation in cancer and 
embryonic stem cells.74 Furthermore, 
certain miRNAs are modified by RNA 
editing, a process that can lead to changes 
in miRNA stability or alter their target 
selection.75-77 As expected, there are also 
examples of transcriptional regulation 
and epigenetic silencing of miRNAs.78,79 
To add to this list of possibilities, a case 
of activation of translation is now also 
described for a miRNA.80 This study shows 
that AGO2 acts, together with the FMRP-
related protein FXR1, as an activator of 
translation when binding to the 3’-UTR of 
tumor necrosis factor-a mRNA in serum-
starved human cells.
Concluding Remarks
The discovery of miRNAs has shown us 
that 3’UTRs, analogous to promoters, are 
a widely used playground for modulators 
of gene expression. The discovery that 
RNA-binding proteins can modulate 
miRNA activity reveals an increasing 
dynamic regulation of gene expression 
that will —no doubt— impact many 
cellular processes. We have recently 
demonstrated that the interplay between 
miRNAs and one such RBP, Dnd1, is 
important for the maintenance of the 
primordial germ cells.2 We show that the 
function of Dnd1 is conserved throughout 
evolution from zebrafish to humans and 
its mechanism involves counteracting 
miRNA binding to target mRNAs. 
However, several questions emerge. For 
instance; what are the (critical) targets 
of Dnd1? What are the protein partners 
of Dnd1? What is the sub-cellular 
localization of Dnd1 target mRNAs? Does 
Dnd1 interact with the miRNP directly? 
Does it influence miRNP activity? Is Dnd1 
function restricted to primordial germ 
cells? Does Dnd1 function contribute to 
prevention of testicular germ cell cancer? 
These, and other questions will have to 
be answered in the future to get a clear 
picture of what Dnd1, and other RBPs do, 
and how a healthy and productive germ 
line is maintained.
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SUMMARY
MicroRNAs (miRNAs) are inhibitors of gene
expression capable of controlling processes in
normal development and cancer. In mammals,
miRNAs use a seed sequence of 6–8 nucleo-
tides (nt) to associate with 30 untranslated re-
gions (30UTRs) of mRNAs and inhibit their ex-
pression. Intriguingly, occasionally not only the
miRNA-targeting site but also sequences in its
vicinity are highly conserved throughout evolu-
tion. We therefore hypothesized that conserved
regions in mRNAs may serve as docking plat-
forms for modulators of miRNA activity. Here
we demonstrate that the expression of dead
end 1 (Dnd1), an evolutionary conserved RNA-
binding protein (RBP), counteracts the function
of several miRNAs in human cells and in primor-
dial germ cells of zebrafish by binding mRNAs
and prohibiting miRNAs from associating with
their target sites. These effects of Dnd1 are me-
diated through uridine-rich regions present in
themiRNA-targetedmRNAs. Thus, our data un-
ravel a novel role of Dnd1 in protecting certain
mRNAs from miRNA-mediated repression.
INTRODUCTION
MicroRNAs (miRNAs) constitute a family of �22 nucleo-
tide (nt) RNAs widely expressed in metazoans (Lee et al.,
1993; Pillai et al., 2007). These regulators of gene expres-
sion are capable of defining and altering cell fate. Recent
estimations suggest the existence of 500–1000 miRNAs
per genome and that a large proportion of human pro-
tein-coding genes are under the regulation of one or
more miRNAs (Aravin and Tuschl, 2005; Lewis et al.,
2005). Evidence suggests that miRNAs participate in the
regulation of a large variety of cellular processes and
that the vast majority of miRNAs show tissue or develop-
mental stage-specific expression (Lagos-Quintana et al.,
2002; Lim et al., 2005;Wienholds et al., 2005). Importantly,
aberrant expression or activity of miRNAs can lead to dis-
ease (Kloosterman and Plasterk, 2006; Pillai et al., 2007;
Voorhoeve and Agami, 2006).
Most miRNAs are transcribed by RNA polymerase II as
long RNAs that are converted to�70-nt-long pre-miRNAs
by Drosha (Lee et al., 2003). The pre-miRNAs are then
exported to the cytoplasm by Exportin 5, converted to
�22 nt mature miRNAs by Dicer, and one strand of the
duplex is incorporated into the RNA-induced silencing
complex (RISC) (Gregory et al., 2005;Maniataki andMour-
elatos, 2005). In animals, miRNAs utilize a seed sequence
at their 50 end (nt 2–8) to associate with 30UTR regions of
mRNAs to suppress gene expression by inhibiting transla-
tion that occasionally is associated with mRNA decay
(Bagga et al., 2005; Lim et al., 2005; Pillai et al., 2005).
RepressedmRNAs, miRNAs, andmost proteins constitut-
ing the miRNA-RISC complex (miRNP) are enriched in
cytoplasmic processing bodies called P bodies. P bodies
are known to be sites of translational repression and
mRNA decay. They are enriched in factors involved in
inhibition of translation and lack ribosomes and transla-
tion-initiation factors (Liu et al., 2005; Pillai et al., 2005).
Importantly, it is becoming increasingly clear that during
their biogenesis, the activity of miRNAs is subjected to in-
tense regulation. For example, the nuclear processing of
certain miRNAs (e.g., let-7 in ES cells) can be repressed
by a yet unknown mechanism (Thomson et al., 2006). Fur-
thermore, certain miRNAs are modified by RNA editing,
a process that can lead to changes in miRNA stability or
alter their target selection (Kawahara et al., 2007; Knight
and Bass, 2002; Yang et al., 2006). Additionally, two
recent reports indicated that miRNA-mediated repression
in neurons is reversible. Treatment of cultured rat neurons
with brain-derived neurotrophic factor leads to partial
relief of Limk1 mRNA repression by miRNA-134 (Schratt
Cell 131, 1273–1286, December 28, 2007 ª2007 Elsevier Inc. 1273
41
Dnd1 inhibits miRNA access to target mRNA
Figure 1. Dnd1 Counteracts the Inhibition of p27 Expression by miR-221
(A) Conservation analysis of p27-30UTR from human to fish (from Kent et al. [2002]). The positions of the two target sequences of miR-221 are marked.
1274 Cell 131, 1273–1286, December 28, 2007 ª2007 Elsevier Inc.
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et al., 2006). This process possibly involves the mTOR
pathway, although the mechanism of miRNA derepres-
sion remains unknown. Second, external stimulation of
Drosophila olfactory neurons induces degradation of the
Armitage protein, which is required for miRNP assembly
(Ashraf et al., 2006). As a result, the translation of the
protein kinase CaMKII mRNA, which is controlled by
miRNAs, is enhanced. Last, the repression of CAT-1
mRNA by miR-122 in hepatocarcinoma cells is relieved
in stress conditions by binding of HuR, an AU-rich ele-
ment-binding protein, to a region at the end of the 30UTR
of CAT-1 (Bhattacharyya et al., 2006).
In addition, evidence in zebrafish suggests that, a subset
of miR-430 targets is protected from repression in germ
cells (Mishima et al., 2006). In particular,miR-430-mediated
repression of nanos1 and TDRD7 is not effective in germ
cells. As specific regions in the 30UTRof these genescoun-
teract their repression in germline cells, it is reasonable to
assume that germ cell-specific factors bind and counter-
act miR-430 function in these cells. Germ cells are known
to contain structures referred to as germplasm that resem-
ble P bodies; these contain an array of RNA-binding pro-
teins (RBPs) giving these cells unique control over transla-
tion and the stability of mRNA and proteins (Kotaja et al.,
2006; Kotaja and Sassone-Corsi, 2007). Together, these
observations indicate that themiRNApathwaycanbecon-
trolled at different levels, from stability, processing, se-
quence identity, and binding to target mRNAs. Here we
show that theRBPdead end1 (Dnd1) prohibitsmiRNA-de-
pendent inhibition of gene expression in humancells and in
zebrafish primordial germ cells.
RESULTS
Dnd1 Relieves miRNA Repression
in Human Germline Cells
Using functional genetic-screening approaches, we have
recently identified themiRNA-mRNA interactions between
p27 and miR-221 and between LATS2 and miR-372 as
promoting cancer (le Sage et al., 2007; Voorhoeve et al.,
2006). Both p27 and LATS2 harbor at their 30UTR two
nearby evolutionary conserved target sequences for
miRNA-221 or -372, respectively, that are required and
sufficient for miRNA function (Figures 1A, S1A, and
S1B). Interestingly, in both cases the conservation was
not restricted to the miRNA-targeting sequences, but
rather included the whole region in between the two
miRNA-targeting sites. This observation suggests that
other factors (proteins or RNA) could associate with these
regions to influence miRNA/mRNA function and/or inter-
action. To investigate the possibility that RBPs influence
the activity of themiRNA pathway, we examined the effect
of expression of several RBPs on miR-221-mediated
repression of p27. We utilized a reporter assay with the
wild-type 30UTR of p27 coupled to luciferase and mea-
sured miRNA-induced repression. We found that human
dead end 1 (Dnd1), a protein whose function is required
for germ cell survival andmigration in zebrafish (Weidinger
et al., 2003), affects miRNA activity. Specifically, cotrans-
fection of Dnd1 diminished miR-221-mediated inhibition
of luciferase-p27-30UTR expression (Figure 1B). Dnd1
had no effect on expression from either a construct
encoding luciferase-p27 30UTR that is mutated at the
two miR-221 sites or on an empty luciferase reporter vec-
tor, suggesting that the increase in luciferase expression
was not caused by a general effect on transcription or
translation efficiency but rather was specific to miRNA-
repressed translation. Similar results were obtained with
LATS2/miR-372 and connexin-43/miR-1 and -206 (Fig-
ure S1C). To further test whether Dnd1 activity depends
on miRNA function we inactivated miRNA synthesis with
an shRNA vector targeting Pasha, a component specific
to the miRNA pathway (Gregory et al., 2004). Figure S1D
demonstrates the inhibitory effect of shPasha on miR-
221 processing. In HEK293 cells, which endogenously ex-
press p27 and miR-221 (Figure 2C), introduction of Dnd1
or inhibition of Pasha, elevated endogenous p27 protein
levels to a comparable extent (�4-fold, Figure 1C). Inter-
estingly, cointroduction of Dnd1 and shPasha did not
cause further elevation in p27 levels, further supporting
the idea that Dnd1 activity depends on miRNA function.
Dnd1 contains a conserved RNA-binding domain that
bears high similarity to that of apobec complementation
factor (ACF), LOC166863, Syncrip, hnRNPR, ELAV4, and
DAZ. To test whether the effect of Dnd1 on miRNA activity
is specific and mediated through its RNA-binding domain,
we used expression plasmids of Dnd1 homologs and
related genes and found neither to significantly inhibit
(B) Expression vectors for miR-221 and human Dnd1 (huDnd1) were cotransfected with the indicated luciferase constructs. Relative luciferase activity
is the ratio between firefly luciferase and renilla control luciferase, adjusted to 100%. An immunostaining with anti-HA antibody demonstrates the
expression of huDnd1 while H2B-GFP was used to control transfection efficiency. The results are represented as means and SD from three indepen-
dent experiments.
(C) HEK293T cells were transfected with the indicated constructs and whole-cell lysates were immunostained with anti-Tubulin, p27, and HA anti-
bodies. p27 protein level was analyzed using Tina 2.0 software (Raytest, Sheffield, UK).
(D and E) Similar to (B), only that several RBPs, as well as the zebrafish Dnd1 homolog (drDnd1) and a mutant in the RNA-binding domain
(drDnd1Y104C), were cotransfected together with pGL3-p27-30UTR and renilla luciferase control.
(F) HEK293T cells were transfected with the indicated constructs and subjected to RPA with probes to detect p27 mRNA and control cyclophilin and
to immunoblot analysis using p27 and control Tubulin antibodies. Quantification of protein levels was performed using Tina 2.0 software (Raytest;
Sheffield, UK).
(G) Tera1 cells were transfected with shDnd1 and subjected to quantitative RT-PCR analysis for LATS2, Dnd1, and GAPDH control. The results are
represented as means and SD from three independent experiments.
(H) Similar to (B), Tera1 cells were transfected with the indicated constructs.
Cell 131, 1273–1286, December 28, 2007 ª2007 Elsevier Inc. 1275
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miR-221-mediated suppression of luciferase-p27 30UTR
(Figure 1D, expression controls shown in Figure S1E). In
contrast, repression of miR-221 activity was observed
also when the zebrafish and mouse homologs of Dnd1
were introduced (Figure 1E and data not shown). Interest-
ingly, transfection of a zebrafish Dnd1 mutated at a single
conserved residue within its RNA-binding domain (Y104C,
a mutant that cannot rescue loss of germ cells when Dnd1
is depleted in zebrafish embryos; K.S and E.R., unpub-
lished data) hampered Dnd1’s ability to inhibit miR-221
function (Figure 1E). Also substituting the RNA-binding
domain of Dnd1 for that of ACF resulted in loss of Dnd1
function (Figure S1F). Collectively, these results suggest
that inhibiting miRNA function is specific to Dnd1 and indi-
cate that for counteracting miRNA activity, Dnd1 requires
an intact RNA-binding domain.
Suppression of gene expression by miRNAs is exerted
by translational inhibition that occasionally is associated
withmRNAdecay (Baggaet al., 2005; Limet al., 2005; Pillai
et al., 2005). To test the possible effect of Dnd1 on these
pathways, we examined the endogenous p27 RNA and
protein levels in HEK293 cells (expressing endogenous
p27 and miR-221and -222, Figure 2C). Figure 1F shows
that transfection of either human or wild-type zebrafish
Dnd1, but not the Y104C mutant, caused elevation in p27
mRNA (up to 1.5-fold) and protein (up to 5-fold), indicating
that Dnd1 can potently block endogenous miR-221 and
-222-mediated mRNA decay and translation inhibition.
Figure 2. Dnd1 Preferentially Associates with mRNAs
(A) MCF-7 cells were transfected with the indicated constructs and subjected to subcellular fractionation to separate nuclear from cytoplasmic
material, and both protein and RNA were extracted. RPA was performed with probes to detect miR-221 and cyclophilin. Immunoblot analysis
was performed with HA antibodies to demonstrate expression of Dnd1 and to detect Cdc6 and Tubulin, to test the purity of fractionation. P is probes
alone, Y is yeast total RNA.
(B) Expression vectors for miR-221 and human Dnd1 (huDnd1) were cotransfected with the indicated luciferase constructs and proceeded as in
Figure 1B. Blue and brown bars represent control and Dnd1 vectors, respectively.
(C) HEK293 cells were cotransfected with the indicated expression constructs and subjected to IP with anti-HA antibodies. RNA was extracted from
80% of each IP and 5% from each input and subjected to RPA analysis to detect p27 and control cyclophilin mRNAs, human telomerase RNA (hTR),
and miR-221. Below, a blow up of p27 signal in control and wild-type IP samples is shown for clarity.
(D) The same amount of extracts from input and IP (marked T and IP, respectively) was used for immunoblot analysis with anti-HA and control anti-
Tubulin antibodies.
1276 Cell 131, 1273–1286, December 28, 2007 ª2007 Elsevier Inc.
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In all our experiments so far we examined the function of
human Dnd1 by ectopic introduction. To study endoge-
nous Dnd1 function, we first tested by quantitative RT-
PCR several human cancer cell lines for the expression
of Dnd1 and found the teratoma Tera1 cell line to be pos-
itive. Interestingly, Tera1 cells express high levels of the
miR-372 family, which we have previously shown to target
LATS2 through two sites at its 30UTR (Figure S1B). We
therefore examined endogenous LATS2 expression in
Tera1 cells following suppression of Dnd1 expression by
an effective shRNA vector (Figure S1G). As Dnd1 affected
both miRNA-mediated translation inhibition and mRNA
stability (Figure 1F), we used quantitative RT-PCR and
found a marked reduction in LATS2 mRNA levels associ-
ated with the inhibition of endogenous Dnd1 expression
(Figure 1G), suggesting that Dnd1 protects LATS2 expres-
sion. To directly measure the effect of endogenous Dnd1
on the activity of endogenous miR-372 family, we used
sensor molecules containing the luciferase gene under
the control of either wild-type LATS2-30UTR or a mutant
in the 372 target sites (le Sage et al., 2007; Voorhoeve
et al., 2006). Figure 1H shows that transfection of shDnd1,
but not a control vector, reduced the expression of a
cotransfected luciferase LATS2 30UTR reporter gene
only when the miR-372 targeting sites were present.
Altogether, these results indicate that endogenous Dnd1
in Tera1 cells protects the expression of endogenous
LATS2 from being targeted by the miR-372 family.
Preferential Association of Dnd1 with mRNAs
Since Dnd1 requires an intact RNA-binding domain to
counteract miRNA function, it is conceivable that Dnd1 in-
terfereswitheither theexpression, theprocessing tomature
miRNA, or the subcellular localizationofmiR-221. To exam-
ine the effects of Dnd1onmiR-221biogenesis,MCF-7 cells
were cotransfected with vectors encoding either human or
zebrafish Dnd1 andmiR-221 or control miRNA, and subse-
quently subjected to subcellular fractionation, RNA isola-
tion, and to an RNase protection assay (RPA) to detect cy-
clophilin control RNA and miR-221 precursor and mature
forms. As shown in Figure 2A, the expression level, effi-
ciency of processing, or subcellular localization of mature
miR-221 were not altered by Dnd1. Western blot analysis
with anti-HAconfirmed the expressionof humanand zebra-
fishproteins,whereasnuclearCdc6andcytoplasmicTubu-
lin verified cellular fractionation (Figure 2A, bottom).
An alternative explanation that could account for Dnd1
activity is that the protein binds miRNAs and inhibits their
function. To test this option we converted one miR-221-
targeting site in p27 30UTR to an RNAi site (named FC,
a full complementary region to miR-221) and mutated
the seed of the second site (Figure 2B). In this way,
p27-30UTR FC was solely subjected to RNAi-mediated
degradation by miR-221. In cotransfection assays, the
presence of Dnd1 did not reduce miR-221 activity toward
p27-30UTR FC, suggesting that Dnd1 was unable to coun-
teract the RNAi pathway. These results are in line with the
assumption that Dnd1 counteracts miR-221 activity either
at the level of RISC-incorporated-mature miR-221 or
downstream, rather than by steric hindrance of miR-221.
Next, we checked whether Dnd1 interacts with mature
miR-221 or with p27 30UTR. We transfected HEK293 cells
with HA-tagged Dnd1, Dnd1Y104C, and as controls HA-
tagged PAK4 and empty vector. We also cotransfected
an expression vector for miR-221 to enhance the possible
association with Dnd1. Subsequently, we subjected
whole-cell extracts to immunoprecipitation (IP) using
anti-HA antibodies, extracted RNA, and performed RPAs
to detect the interactingRNAs. This analysis revealed clear
binding of Dnd1 to endogenous p27 and cyclophilin
mRNAs but not to hTR, a nontranslated-RNA coding for
human telomerase RNA (Figure 2C) (Kedde et al., 2006).
The interaction of Dnd1 with p27 and cyclophilin required
its intact RNA-binding capacity, as no apparent interaction
was observedwith theDnd1Y104Cmutant. Furthermore, no
specific association was detected with miR-221, even
when itwascotransfectedwithDnd1. Immunoblot analysis
with HA antibody confirmed the expression and equal
immunoprecipitation of Dnd1 and PAK4 (Figure 2D). Alto-
gether, these results demonstrate that Dnd1 bindsmRNAs
but not miRNAs to block miRNA activity.
Dnd1 Alleviates miR-430 Repression of Nanos1
and TDRD7 in Primordial Germ Cells of Zebrafish
We next examined the function of Dnd1 in zebrafish to
question whether the relief of mRNA-mediated repression
described above is part of the in vivo function of Dnd1 in
the context of a developing organism. Whereas Dnd1
has been shown to be essential for germline development
in zebrafish andmouse, the actual molecular mechanisms
by which it exerts its function are unknown (Weidinger
et al., 2003; Youngren et al., 2005). We followed the
expression changes of three germline specific genes:
nanos1, TDRD7, and Vasa. The specific expression of
nanos1 and TDRD7 in the PGCs is considered to be the
result of miR-430-dependent inhibition in somatic cells,
while Vasa regulation is miR-430 independent (Mishima
et al., 2006). Indeed, mutating the single miR-430 site in
the 30UTR of either nanos1 or TDRD7 results in ubiquitous
expression. However, while PGCs allow nanos1 and
TDRD7 expression, they also express miR-430, suggest-
ing that miR-430-induced repression of these genes is
suppressed in PGCs (Mishima et al., 2006).
To study Dnd1 function, we knocked down the transla-
tion of the gene in zebrafish embryos using morpholino
antisense oligonucleotides. RNA was extracted from
these embryos, and the endogenous levels of the germ-
line-specific genes (nanos1, TDRD7, and Vasa) were com-
pared to Odc1, a ubiquitously expressed gene. In line with
our hypothesis, the inhibition of endogenous Dnd1 caused
a marked reduction in endogenous nanos1 and TDRD7
mRNA levels, but not Vasa (Figures 3A and S2A). Then,
we cloned the 30UTRs of nanos1, TDRD7, and control
Vasa downstream of fluorescencemarker genes, to deter-
mine whether the Dnd1 effect is mediated through their
30UTR. Similar to the endogenous expression pattern,
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Figure 3. Zebrafish Dnd1 (drDnd1) Counteracts Inhibition of Nanos by miR-430
(A) One-cell-stage zebrafish embryos were injected with Dnd1 morpholino or control morpholino. RNA was extracted and subjected to quantitative
RT-PCR analysis to compare endogenous levels of nanos1 and vasa to odc, and nanos to vasa.
(B) One-cell-stage zebrafish embryos were coinjected with DsRed-nos1-30UTR and gfp-vasa-30UTR together with dead end morpholino or control
morpholino.
1278 Cell 131, 1273–1286, December 28, 2007 ª2007 Elsevier Inc.
46
Chapter 3
the injection of RNA, encoding a fluorescent marker gene
fused to the 30UTR of nanos1, TDRD7, or Vasa, into zebra-
fish embryos leads to preferential fluorescence in PGCs
(Koprunner et al. [2001] and data not shown). Upon
Dnd1 knockdown, quantitative pixel-intensity analysis
shows a clear and significant reduction in red fluorescent
signal (DsRed-nos1 30UTR or DsRed-TDRD7 30UTR), but
not green (coinjected GFP-vasa 30UTR) in PGCs (Figures
3B and S2B), indicating that Dnd1 affects gene expression
through the 30UTR of nanos1 and TDRD7. Next, we
examined whether the reduction in nanos1 and TDRD7
following loss of Dnd1 depends on the ability of miR-430
to interact with these genes. Both nanos1 and TDRD7
harbor one miR430-targeting site (Figures 3C and S2C).
We therefore compared the expression of marker genes
fused to a wild-type or a mutated miR-430-targeting site
in nos1 30UTR and TDRD7 30UTR. Quantitative pixel-inten-
sity analysis showed that the reduction in fluorescence
resulting from knocking down Dnd1 function was effec-
tively suppressed by mutating the miR-430-targeting site
(Figures 3C and S2C). Altogether, our data suggest that
Dnd1 functions to relieve miR-430-mediated nanos1 and
TDRD7 inhibition in zebrafish PGCs.
U-Rich Regions Mediate Dnd1 Binding
and Function
Dnd1 contains two single-strand RNA recognition motifs,
spanning approximately residues 60–131 and 140–213.
Our data suggest that these domains bind mRNAs at
specific sites. A BLASTP search of the Dnd1 sequence
against the database of known structures (the PDB)
revealed several significant homologs (E values of 10�5
and 10�3) and allowed straightforward homology-based
modeling using the SWISS-MODEL server (Schwede
et al., 2003). Superimposing the two homology-modeled
domains in the structure of the similar Drosophila sex-
lethal protein bound to uridine-rich single-stranded RNA
indicated clearly that Dnd1 has all the hallmarks necessary
to bind U-rich single-stranded RNA (Handa et al., 1999).
We therefore reasoned that Dnd1 might also bind U-rich
regions (URRs). Interestingly, two URRs are found in
between the two miR-221-binding sites in p27 30UTR
(Figure 4A, marked purple). To test whether the region in
between the two miRNA sites is sufficient to confer
Dnd1 activity, we cloned it into a luciferase reporter vector
(p27 30UTR(196–300)). Figure 4B shows that this minimal
region is sufficient to allow full repression by miR-221
and derepression by Dnd1. To more specifically address
the role of the URRs, we generated two mutants: mutant
1, in which the two URRs were replaced by non-URRs,
and mutant 2, where adjacent sequences were similarly
mutated as control. Importantly, mutating the URRs, but
not the adjacent sites, conferred resistance to the Dnd1
effect (Figure 4C). No significant change in the repression
activity of miR-221 was noted in mutant 2 (data not
shown), indicating that these mutations did not affect
miR-221-mediated repression of the p27 30UTR. To fur-
ther investigate the role of each URR, three more mutants
were produced where either URR 1 or 2 were mutated
(Figure 4A). Both mutants supported full Dnd1 activity
(Figures 4C and 4D), suggesting that Dnd1 requires at
least one URR adjacent to the miR-221 sites to function.
Next, we examined whether the URRs serve as docking
sites for Dnd1. We immunoprecipitated (IP) HA-tagged
Dnd1, Dnd1(Y104C), or control proteins from HEK293 cells
and incubated them with RNA purified from MCF-7 cells
expressing control vector, wild-type, or mutant 1 lucifer-
ase-p27 30UTR(196–300). As detected by RPA on the bound
material, a clear and significant enrichment of lucifer-
ase-p27 30UTR(196–300) was observed when wild-type
Dnd1-HA was used for the pull down assay (Figure 4E).
In contrast, no significant pull down of luciferase was
observed when the URRs of luciferase-p27 30UTR were
mutated (mutant 1) or with Dnd1(Y104C). The specificity of
the binding as well as the equal efficiency of pull-down
was demonstrated by absence of binding between Dnd1
and endogenous hTR, while equal precipitation of endog-
enous cyclophilin was seen in all extracts (Figure 4E).
Although we cannot rule out that mutations in URRs
have effects on the binding of other RBPs, our results sug-
gest that Dnd1 binds URRs and thereby mediates sup-
pression of miRNAs.
To test the in vivo relevance of URRs to Dnd1 function,
we mutated URRs found within the zebrafish nos1 and
TDRD7 30UTRs and tested the effect of these mutations
on gene expression. Figure 5A shows that mutating one
URR (mut3, downstream of miR-430 site) of nos1 30UTR
reduced its expression. Similar results were obtained
with TDRD7 30UTR (Figure S2D). To test whether the effect
of URR mutation was dependent on miRNA function, we
introduced the mutation of the URR in the background
of the miR-430 target-site mutant. Figure 5B shows that
mut3 did not reduce gene expression when miR-430 tar-
get site was mutated, suggesting that also in this case
Dnd1 effect is miRNA dependent.
Mechanism of Dnd1 Function
Our results point to a model by which Dnd1 positively
regulates gene expression by prohibiting miRNA-medi-
ated gene suppression. To test this model we examined
the direct interaction of miR-221 with its target p27 in hu-
man HEK293 cells, in the presence or absence of human
Dnd1. We designed a synthetic RNA duplex mimicking
miR-221where the sense oligo was taggedwith a 30-biotin
group for efficient pull-down using streptavidin beads. As
control, we used a seed mutated, biotin-tagged, miR-221
(C) One-cell-stage zebrafish embryos were coinjected with RNA containing the venus open-reading frame fused to the wild-type nanos1 30UTR
(30nos1wt), RNA containing the cfp open-reading frame fused to the miR-430-binding site mutated nanos1 30UTR (cfp-30nos1mut1) and vasa-dsRed
(for labeling the germinal granule for easier identification of germ cells) together with dead endmorpholino or control morpholino. Error bars depict the
standard error of the mean (SEM); the p value was calculated using t test.
Cell 131, 1273–1286, December 28, 2007 ª2007 Elsevier Inc. 1279
4
Dnd1 inhibits miRNA access to target mRNA
Figure 4. Binding of Dnd1 to URRs Mediates Derepression of p27 Inhibition by miR-221
(A) A diagram aligning the sequence area in p27-30UTR containing the two miR-221 target regions. In red are regions mutated in the indicated
constructs.
(B–D) Luciferase reporter assay were performed as in Figure 1B using the indicated pGL3-p27-30UTR constructs and the expression vectors for
huDnd1 and miR-221. The results are represented as means and SD from three independent experiments.
(E) HEK293 cells were transfected with the indicated Dnd1-HA expressing vectors, and Dnd1 was IPed using anti-HA antibody. Immunoblot analysis
shows the expression and IP of Dnd1.MCF-7 cells were transfected with luciferase-p27-30UTR constructs; RNAwas extracted after 48 hr and equally
divided between the IPs. Beads were incubated with the RNA for 45 min at 6�C, washed, and subjected to RPA using probes to detect luciferase and
cyclophilin mRNAs, and the noncoding human telomerase RNA (hTR).
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duplex. The activity of these taggedmolecules toward p27
30UTR was verified in a luciferase assay (Figure S3) and
Dnd1 toward p27 in western blot (Figure 6A, left). As
HEK293T cells express miR-221, exogenous introduction
of miR-221 results in only a slight effect on p27 expres-
sion, while introduction of human Dnd1 raises p27 levels
(see also Figure 1C). Subsequently, we examined whole-
cell extracts and pull-downs from the same cell popula-
tions using RPA and detected a specific association
between wild-type miR-221 and endogenous p27 mRNA
(Figure 6A, middle and right panels). No specific interac-
tion was observed with hTR, our negative control. Most
intriguingly, introduction of human Dnd1 completely abol-
ished the interaction of miR-221 with p27 mRNA, indicat-
ing that Dnd1 inhibits miR-221 accessibility. Collectively,
our results indicate that Dnd1 counteractsmiRNA function
by binding URRs in 30UTRs of mRNAs and reducing their
affinity to miRNAs (Figure 6B). However, we cannot ex-
clude at this point that additional functions, such as coun-
teracting RISC activity or subcellular sequestration, may
contribute to Dnd1 activity.
DISCUSSION
In this study we provide evidence that primordial germ
cells possess factors such as Dnd1 that protect the ex-
pression of several genes from repression by miRNAs,
as exemplified by miR-430. The expression of at least
some miR-430 RNA targets, such as nanos1 and
TDRD7, is allowed in primordial germ cells in the presence
of miR-430. Similarly, the expression of LATS2, a target
gene for the miR-372-family, is dependent on the expres-
sion of Dnd1 in Tera1, a human cell line derived from
a germ-cell tumor that contains high levels of the
miR-372 family. Our findings provide an explanation for
this phenomenon. We suggest that Dnd1 suppresses
miR-430 and miR-372-family function toward several of
its mRNA targets by binding to URRs that are located
within these mRNAs. Our results pinpoint the mechanism
by which Dnd1 exerts its function. Binding of Dnd1 to
mRNAs prohibits miRNA interaction.
Dnd1 in Germ-Cell Development
Both in zebrafish and in mouse, Dnd1 is essential for
germ-cell survival, whereas in the 129-mouse background
it induces testicular germ-cell tumors (TGCTs) arising from
the few germ cells that develop in the absence of Dnd1
(Weidinger et al., 2003; Youngren et al., 2005). These tu-
mors resemble human testicular germ-cell tumors, which
are the most common cancers affecting young men (Oos-
terhuis and Looijenga, 2005; Youngren et al., 2005). It
remains to be established which mutation(s) from the
129 strain synergize with the Dnd1 mutation to cause
the development of TGCTs. However, recently three pro-
tein-coding genes, from which two are RBPs and one
miRNA, were identified to be candidate disease genes
from the 129 strain (Zhu et al., 2007). Additionally, a recent
finding in C. elegans showed that disruption of the germ
plasm by loss of two genes involved in RNA biology in
these animals can also lead to the development of similar
tumors (Ciosk et al., 2006). Our results demonstrate that
loss of Dnd1 enhances miRNA repression of some genes
that are essential for primordial germ-cell development
(Koprunner et al., 2001) (among them nanos1 and
TDRD7) and predict that this mechanism can be responsi-
ble for defects in germ-cell survival or for tumor formation.
Whether protection of mRNAs from miRNAs is the only
function of Dnd1 in germ cells remains to be investigated.
Nevertheless, our results show that counteracting or bal-
ancing miRNA function is important during development,
at least to maintain viable and functional germ lines in
zebrafish and mouse.
Dnd1 and Other RBPs
Recent publications have implicated mechanisms that
counteract the activity of miRNAs on specific mRNAs
(Ashraf et al., 2006; Bhattacharyya et al., 2006; Schratt
et al., 2006). Together with these studies, our data unveil
a dynamic regulation of miRNA suppression on the
30UTRs of target mRNAs. The most relevant work showed
that HuR (ELAV1), an AU-rich element (ARE) binding pro-
tein, relieves CAT-1 mRNA from miR-122-mediated
repression, a process that involves binding of HuR to the
30UTR of CAT-1 mRNA (Bhattacharyya et al., 2006). The
mechanism of HuR action is yet unknown. Here, we iden-
tified Dnd1, another RBP, whose activity is comparable to
HuR. However, our results highlight several differences
between Dnd1 and HuR. While Dnd1 depends on URRs
to relieve the miRNA repression, HuR depends on
AU-rich elements. Second, Dnd1 seems to have a broad
effect, as we have strong evidence showing that the re-
pression of p27 by miR-221, LATS2 by miR-372, con-
nexin-43 by miR-1 and -206 (Anderson et al., 2006), and
Nanos and TDRD7 by miR-430 in zebrafish PGCs, are all
being antagonized by Dnd1; for now HuR seems to have
a more restricted function, suppressing CAT-1 expres-
sion. Last, the expression of HuR is induced following
stress in liver cells, whereas Dnd1 expression is restricted
to primordial germ cells and certain neuronal tissues
(Youngren et al., 2005). By binding to mRNA, Dnd1 pre-
vents miRNA-mediated repression. Whether this is a gen-
eral mechanism applicable to HuR, or other RBPs,
remains to be seen.
Counteracting miRNAs and siRNAs
Our work shows that Dnd1 activity can counteract gene si-
lencing induced by miRNAs but not by siRNA-mediated
RNA interference (RNAi). When one miR-221-targeting
site in p27 30UTRwas converted to a full miR-221 comple-
mentary sequence (Figure 2B) as well as when a fully com-
plementary shRNAwas used to target the 30UTR of LATS2
(Figure S4), Dnd1 function was lost. Since Dnd1 associ-
ates with mRNA and not with miRNAs, we can envision
two possibilities that could provide an explanation. (1)
Dnd1 binding could change the RNA structure to be unfa-
vorable for miRNA binding by, for example, enforcing
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a secondary structure that hides the sequence required
formiRNA-seed recognition. As siRNAs do not entirely de-
pend on seed sequences and their association with
mRNAs is tighter, their binding to 30UTRs could therefore
be less affected. (2) Dnd1 could localize mRNAs to loca-
tions in the cell that are not accessible tomiRNA-mediated
silencing but still mRNA degradation by an RNAi-medi-
ated mechanism is possible.
30UTRs as Binding Platforms
for Regulating miRNAs and RBPs
Our results strongly suggest that the 30UTRs of at least
some mRNAs are binding platforms for both miRNAs
that repress translation and RBPs that regulate this re-
pression. In particular, RBPs can restore gene expression
in the presence of inhibitory miRNAs. This mode of regu-
lation has several consequences. First, as it affects protein
synthesis and mRNA stability rather than controlling the
expression of miRNAs in the cells, it is potentially a very
rapid mechanism. Second, relief of repression can be
exerted simultaneously on only a subset of the miRNA-
targeted mRNAs, thereby giving modularity to miRNA
function. Third, it adds robustness to expression patterns
as different RBPs can in principle relieve the repression of
different sets of mRNAs, even if these are regulated by the
same miRNA. Fourth, this mechanism allows differential
gene regulation in different tissues while keeping the ex-
pression of both miRNAs and mRNAs constant in the
cell. One implication of this mode of regulation is that
the presence of a miRNA and its target in the same tissue
does not necessarily result in repression, therefore allow-
ing coexpression of both miRNA and target mRNA. How-
ever, how broad Dnd1 function is: how many mRNAs and
how many miRNAs are affected by Dnd1 remains to be
Figure 5. URRs Are Required for Dnd1 to Efficiently Repress miR-430-Mediated Nanos Inhibition
(A) RNA containing the DsRed open-reading frame fused to the wild-type nanos1 30UTR (30nos1wt) was coinjected into one-cell-stage zebrafish
embryos together with RNA containing the gfp open-reading frame fused to different versions of the nanos1 30UTR. The different nanos1 30UTRs
that were used are shown above; mutations are marked in red. The ratio between the signal intensity provided by GFP whose open-reading frame
was fused to either one of the nanosUTRswas divided by that originating fromDsRed thatwas fused to thewild-type nanosRNAUTR. Representative
single cells are shown in the right panels.
(B) An experimental setting similar to that described in (A) was used to examine the function of nanosUTR containing a combination ofmutations in the
miR-430 and putative Dnd-binding sites. The different nanos1 30UTRs that were used are shown above; mutations are marked in red. The ratio
between the signal intensity provided dividing the signal intensity of GFP by that of DsRed whose open-reading frame was fused to the wild-type
nanos RNA UTR. Representative single cells are shown in the right panels. Error bars depict the standard error of the mean (SEM); p value was cal-
culated using Ttest.
Figure 6. Mechanism of Dnd1 Function
(A) HEK293T cells (endogenously expressing miR-221 and p27) were transfected as indicated. Cells were harvested 48 hr later and subjected to pull-
down assay with streptavidin beads. Pull-down and whole-cell extracts were analyzed by immunoblot and RPA. Note, because HEK293T cells
endogenously express miR-221, only a moderate reduction in p27 level was observed upon introduction of miR-221 oligos, while Dnd1 expression
induced p27 expression. The results are represented as means and SD from three independent experiments.
(B) Schematic model depicting the mechanism of Dnd1 action. The miRNA-RISC loaded with miRNAs targeting a 30UTR inhibits its translation (upper
panel). By binding to URRs in the 30UTR, Dnd1 prevents miRNAs from binding to and inhibiting translation, thereby prohibiting miRNA function (lower
panel). CR is coding region.
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elucidated. Our results indicate that several mRNAs and
miRNAs are potentially regulated by Dnd1. Genome-
wide proteome and RNome analysis comparing normal




miR-Vec constructs were described before (Voorhoeve et al.,
2006), and Dnd1 open-reading frames were cloned as described
(Weidinger et al., 2003) into a pCS2-based CMV expression vector
to contain a double carboxy-terminal HA tag. Dnd1 homologs ACF
(IOH52413.1), HNRPR (IRALp962F134.1), LOC-166863 (IRAKp961
H0534.1), and SYNCRIP (IRATp970H1055D) were similarly cloned
into this vector (sequences obtained from RZPD Deutsches Ressour-
cenzentrum für Genomforschung GmbH; Berlin, Germany). The PAK4-
HA expression vector was described (Wells et al., 2002). The 30UTRs of
p27 and connexin-43 were PCR amplified from genomic DNA and
cloned into pGL3 (Promega) downstream of the luciferase gene; con-
structs bearing the LATS2 30UTR were described (Voorhoeve et al.,
2006). The mutations in pGL3-p27mut-30UTR were cloned by PCR to
contain the following sequences from the original 30UTR from nt
183–282: GCCTCTAAAAGCGTTGGGGATCCCATTATGCAATTAGG
TTTTTCCTTATTTGCTTCATTGTACTACCTGTGTATATAGTTTTTACC
TTTTGGATCCCAC. In italics are the BamHI sites that substituted the
two seed sequences. The other mutants were similarly cloned to
contain the following sequences from nt 183–282; miRNA seeds













ccttttatgtagcac. Constructs for RPA detection of hTR and cyclophilin
were described (Kedde et al., 2006), antisense probes for detection of
p27 (nt 340–577) and firefly luciferase (nucleotides 0–156) were gener-
ated by PCR, a T7 promoter sequence was included for labeling.
shRNA for pasha was described before (Gregory et al., 2004); the
shDnd1 sequence is GCAGCGACTTCGCCAGCAG—this was cloned
in pSUPER. All constructs were sequence verified.
Antibodies used were CDK4 (C-22), HA Y-11 (sc805), Cdc6 180.2
(sc9964) from Santa Cruz Biotechnology, Tubulin (YL1/2 ECACC),
and rabbit GFP.
Cell Culture, Transfections, and Dual
Luciferase-Activity Analysis
MCF7 andHEK293 cells were cultured in DMEMand Tera1 inMcCoy’s
5A supplemented with 10% heat-inactivated fetal calf serum in 5%
CO2 at 37
�C. For protein-expression analysis and immunoprecipita-
tion HEK293 cells were transiently transfected using calcium-phos-
phate precipitation.
MCF7- and Tera1 cells were transfected using PEI (Polysciences,
Inc.) or Fugene (Roche), respectively, for luciferase analysis with
10 ng of reporter, 5 ng of renilla control plasmid, and 250 ng of either
miR-Vec or miR-Vec control, and 250 ng of either miR-Vec control or
expression plasmid for Dnd1 or homologs. Dual luciferase-activity as-
says were performed 48 hr after transfection according to the manu-
facturer’s directions (Promega). The results are represented as means
and standard deviation (SD) from three independent experiments.
Immunoprecipitation, Western Blotting, miRNA Pull-Down,
and RNase Protection Assays
Dnd1 was IPed from extracts of transfected HEK293 cells using Gam-
maBind G Sepharose (GE Healthcare). Extracts were made and beads
were washed with lysis buffer (125 mM NaCl, 50 mM HEPES (pH 7.5),
0,1% Nonidet P-40, 0.5% Tween-20, 10 mM MgCl2, and protease
inhibitor mixture [Roche Applied Science]). Interaction studies were
performed with total RNA from transfected MCF7 cells extracted
with Trizol reagent (Invitrogen) and split over IP samples in 50 ml lysis
buffer suplemented with RNase-OUT (Invitrogen). Reactions were
carried out for 45 min in an orbital shaker placed at 6�C; thereafter,
beads were washed and RNA was extracted to be subjected to RPA.
For western blot analysis, extracts were separated on 10% SDS-
PAGE gels and transferred to Immobilon-P membranes (Milipore).
Western blots were developedwith Supersignal (Pierce) or ECL (Amer-
sham Biosciences) and exposed to film (Kodak). Cellular fractionation
was performed onMCF7 cells with NE-PER kits fromPierce, according
to manufacturer’s instructions.
Pull-downs with miRNAs were performed with miRNA oligos where
the sense strand contains a biotin group at its 30 end (Dharmacon) in
the mutant miRNA the seed (AGC UAC AUU) was mutated to AGG
AUC CUU. Cells were transfected with FuGENE (Roche) (150 nM
miRNA and 10 mg of control or Dnd1 vector) and after 48 hr lysed
in 20 mM Tris with pH 7.5, 200 mM NaCl, 2.5 mM MgCl2, 0.05%
NP40, 60U RNaseOUT/ml (invitrogen), 1 mM DTT, and protease inhib-
itors (Roche). miRNAs were pulled down with streptavidin sepharose
beads (GE healthcare) preblocked with yeast tRNA (Invitrogen) and
RNase free BSA, (Ambion), and washed four times with lysis buffer.
RNA was extracted and subjected to RPA.
RPAs for Luciferase, p27, cyclophilin, and hTR were performed
using the HybSpeed RPA and MAXIscript kits from Ambion as de-
scribed (Kedde et al., 2006). For miR-221 we used mirVana kits
(Ambion) according to the manufacturer’s instructions and the primer
GCAACAGCTACATTGTCTGCTGGGTTTCAGGCTcctgtctc. We used
2 mg of total RNA (�2% of input) and half of IP samples per reaction.
Quantitative RT-PCR Analysis
RNA was extracted using Trizol reagent (Invitrogen), and cDNA (from
3 mg RNA) was synthesized with superscript III and primed with oligo-
dT according to manufacturer’s instructions (Invitogen). Primers for
zebrafish qPCRwere nanos1 For/Rev: AGACTGAGGCCGTGTACACC
TCTCACTACT / GAGCAGTAGTTCTTGTCCACCATCG, ODC For/Rev:
ACACTATGACGGCTTGCACCG / CCCACTGACTGCACGATCTGG,
vasa1 For/Rev: CCTGCTGCCTATCCTACAGC / CAGGTCCCGTATGC
AAACTT, TDRD7 For/Rev: TCTACCCAGCGGAAGCTTTA / CTGG
TGTCCCACTGGTCTTT. Primers for human Dnd1 were For/Rev: CT
CCACAGGCACCCTGAATG / GGTGCCATAGGTCCCTGTCC; other
primers were as described (Voorhoeve et al., 2006). Analyseswere car-
ried out using SYBR Green PCR master mix (Applied Biosystems) and
Chromo 4 system (BioRad Laboratories).
Zebrafish Strain and Fish Maintenance
Zebrafish (Danio rerio) of the AB genetic background were maintained,
raised, and staged as previously described (Kimmel et al., 1995; West-
erfield, 1995).
Morpholino Knockdown of Dnd1
The dead end morpholino antisense oligonucleotide (dnd MO, 50-GC
TGGGCATCCATGTCTCCGACCAT-30) and the standard control MO
were obtained fromGenetools, Philomath, OR. Six hundred picograms
were injected into one-cell stage embryos to efficiently knock down
Dnd1 function (Weidinger et al., 2003).




Capped sense RNA was synthesized using the mMessageMachine kit
(Ambion) andmicroinjected into one-cell stage embryos. The following
constructs were used: pSP64T-mgfp-vasa-30UTR (GFP-30vasa in
Figure 3A) (Wolke et al., 2002), pSP64T-mgfp-nos1-30UTR (Koprunner
et al., 2001), pSP64T-vasa-dsRedEx-nos1-30UTR (Ds-Red-30nos1 in
Figure 3B), pSP64T-dsRedEx-nos1-30UTR, T3-venus-nos1-30UTR
(30nos1wt in Figures 3C and 5). To obtain a mutation in the miR-430-
binding site pSP64T-ecfp-nos1-30UTR was amplified using primers
(GTCTTTTTGTGTGTGTGTAT and CAAAATCAAACAGTGAACGC) re-
sulting in pSP64T-ecfp-nos1-30UTRmut1 (30nos1mut1 in Figure 3C).
To obtain a mutation in the putative Dnd interacting sequence 1
pSP64T-mgfp-nos1-30UTR was amplified using primers (CAGCA
CTTTTTGTGTGTGTGTATA and GCTCAAACAGTGAACGCACACAT)
resulting in pSP64T-mgfp-nos1-30UTRmut2 (30nos1mut2 in Figure 5).
To obtain a mutation in the putative Dnd-interacting sequence 2
pSP64T-mgfp-nos1-30UTR was amplified using primers (CAGTGTGC
ACTGGTGTTGTGTT and GCTAAAACACAGCAAACACACACA) result-
ing in pSP64T-mgfp-nos1-30UTRmut3 (30nos1mut3 in Figure 5). To
obtain a double mutation in both putative Dnd-interacting sequences
pSP64T-mgfp-nos1-30UTRmut2 was amplified using primers (CAGTG
TGCACTGGTGTTGTGTT and GCTAAAACACAGCAAACACACACA)
resulting in pSP64T-mgfp-nos1-30UTRmut2+3 (30nos1mut2+3 in Fig-
ure 5). To obtain a double mutation in the putative Dnd-interacting
sequence 2 and in the miR-430-binding site, pSP64T-mgfp-nos1-
30UTRmut1 was amplified using primers (CAGTGTGCACTGGTGT
TGTGTT and GCTAAAACACAGCAAACACACACA) resulting in
pSP64T-mgfp-nos1-30UTRmut1+3 (30nos1mut1+3 in Figure 5). To
obtain a triple mutation in both putative Dnd-interacting sequences
and in the miR-430-binding site, pSP64T-mgfp-nos1-30UTRmut2+3
was amplified using primers (GTCTTTTTGTGTGTGTGTAT and ACCT
GGCTCAAACAGTGAACGC) resulting in pSP64T-mgfp-nos1-30UTR
mut1+2+3 (30nos1mut1+2+3 in Figure 5). To obtain pSP64T-ds
RedEx-TDRD7-30UTR (30TDRD7 in Figures S2B and S2C), pSP64T-m
gfp-TDRD7-30UTR (30TDRD7wt in Figure S2D) and pSP6T-eyfp-
TDRD7-30UTR the 30UTR of TDRD7 (EF643554) was amplified using
primers (AAACTCGAGTACTCTCAGAACTGCACTTTC and AAATCT
AGATAATACAACAAAACCTGAACACC) and cloned into correspond-
ing vectors. To obtain a mutation in the miR-430- binding site
pSP64T-mgfp-TDRD7-30UTR was amplified with primer (TCTTTG
GTTTGTTTTGCTGTGTTT/CCAAAATCAAAAAGTACAAACAATG) and
subloned into an ecfp-containing vector resulting in pSP64T-ecfp-
TDRD7-30UTRmut1 (30TDRD7mut1 in Figure S2). To obtain a mutation
in the putative Dnd-interacting sequence 2 pSP64T-mgfp-TDRD7-30U
TR was amplified using primers (CAGCACTTTGGTTTGTTTGCT and
GCTCAAAAAGTACAAACAATGC) resulting in pSP64T-mgfp-TDRD
7-30UTRmut2 (30TDRD7mut1 in Figure S2).
Fluorescence Microscopy and Imaging of Live Cells
Images were obtained using a Zeiss Axioplan2 microscope controlled
by the Metamorph software (Universal Imaging). Average pixel inten-
sity in germ cells was measured and subtracted from the background
signal using the ImageJ software. Error bars represent the SEM. The
p values were calculated using t test.
Supplemental Data
Supplemental Data include four figures and can be found with this
article online at http://www.cell.com/cgi/content/full/131/7/1273/
DC1/.
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The human telomerase RNA (hTR), together with the
telomerase reverse transcriptase, hTERT, constitute the core
components of telomerase that is essential for telomere
maintenance.While hTR is ubiquitously expressed, hTERT is
normally restricted to germ cells and certain stem cells, but
both are often deregulated during tumorigenesis. Here, we
investigated the effects of changes in hTR cellular levels. Sur-
prisingly, while inhibition of hTR expression triggers a rapid,
telomerase-independent, growth arrest associated with p53
and CHK1 activation, its increased expression neutralizes
activation of these pathways in response to genotoxic stress.
These hTR effects are mediated through ATR and are suffi-
ciently strong to impair ATR-mediated DNA-damage check-
point responses. Furthermore, in response to low UV radia-
tion, which activates ATR, endogenous hTR levels increase
irrespective of telomerase status. Thus, we uncovered a novel,
telomerase-independent, function of hTR that restrains ATR
activity and participates in the recovery of cells from UV
radiation.
Most human somatic cells have a limited replicative lifespan
when propagated in vitrowhich is due to their inability tomain-
tain chromosome ends, the telomeres (1, 2). Telomeres are spe-
cialized DNA-protein structures that preserve the integrity of
the ends of the chromosomes and the stability of the genome
(2). However, with each cell division telomeres are shortened
andonce one ormore erode to a certain critical point, the short-
ening induces aDNAdamage checkpoint, thereby posing a bar-
rier to continued cell growth and, therefore, to cancer (3–8).
Cells that escape replicative senescence by inactivating critical
cell cycle checkpoint genes, such as p53, continue to erode their
telomeres, eventually reaching a point that is called crisis (9).
The only way to escape crisis is to ensure that telomeres are
maintained. Most cells do this by reactivating telomerase, but
alternative mechanisms (ALT),2 involving recombination, are
also observed (10–12).
Telomerase, or TERT, is a ribonucleoprotein that copies a
short RNA template into telomeric DNA, thereby maintaining
eukaryotic chromosome ends and preventing replicative senes-
cence (13, 14). Telomerase activity is low or absent in normal
human cells but is high during development in certain stem
cells, germ cells, and 80–90% of human cancers and immortal-
ized human cell lines (10, 11, 15, 16). In fact, telomerase expres-
sion is sufficient for immortalization of primary human cells,
rendering them insensitive to replicative senescence and crisis
(17).
In humans, the core components of the telomerase complex
are the protein catalytic subunit hTERT and the telomerase
RNA subunit hTR (14, 18). hTR is transcribed by RNA poly-
merase II and is 3� processed to generate a 451-nucleotide-long
mature transcript. Its secondary structure is very well con-
served with telomerase RNAs from several vertebrate species,
indicating an important role for RNA structure in telomerase
function (19). Several proteins have been described to bind to
hTR and these are involved in hTR stability, maturation, accu-
mulation, and functional assembly of the telomerase ribonucle-
oprotein complex (2). Certain mutations or deletions in hTR
lead to a rare skin and bone marrow failure syndrome called
dyskeratosis congenita, which is believed to be caused by defec-
tive telomere maintenance in stem cells (20, 21). As expression
of hTRhas been found to be essential for telomeremaintenance
in human disease and also for telomere length maintenance in
mouse models, it is expected to be up-regulated in cancer cells
(22). Indeed, several studies have shown that hTR up-regula-
tion is an early event in tumorigenesis and that hTR levels cor-
relate better to tumor grade than telomerase activity or hTERT
expression (23–31). Up-regulation of hTR was also found to be
an early event in mouse models of tumorigenesis. Here, telom-
erase RNA levels did not parallel the amount of telomerase
activity detected (32, 33). These studies show that even in
tumors that lacked telomerase activity, telomerase RNA was
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ATR regulation by hTR
arable from its role in telomerase activity (32). Contrasting
these observations are mice in which mouse telomerase RNA
(mTR)was deleted from the germ line. Thesemice are viable for
six generations until telomeres have completely eroded (34).
However, the first generation of these mice, which still have
long telomeres, have less skin tumors than wild-type mice fol-
lowing skin chemical carcinogenesis, indicating for some
telomerase-independent effects of mTR (35). This argues that
most mTR function is dependent on telomerase. However, as
germ line gene knock-out may allow for compensating events
to occur while acute inhibition in somatic cells may not (36),
inhibition of telomerase RNA by RNA interference in cancer
cell lines may expose its telomerase independent functions.
Telomeres are intimately linked with DNA damage
responses. Dysfuctional telomeres are recognized as damaged
DNA and directly associate with many DNA damage response
proteins (37). Moreover, the main cellular transducers of DNA
damage, ATM and, to a lesser extent, ATR, have been shown to
play an important role in telomere homeostasis (38, 39). ATM
andATR are phosphatidylinositol 3-kinase-like protein kinases
(PIKKs) that coordinate the repair, cell cycle checkpoint, and
apoptotic responses to DNA damage (40). Loss of ATM causes
telomere decapping and shortening in every organism investi-
gated thus far, and TRF2, a telomeric DNAbinding protein, has
been shown to bind and inhibit ATM activation (37, 41). Prob-
ing a telomeric function for ATR in mammalian cells has not
been possible since ATR is essential for cell viability (42). Inter-
estingly, a recent report has shown that in Arabidopsis ATR is
required for maintenance of telomeric DNA (43). Thus, PIKKs
function in telomere homeostasis and telomeres with their
telomere-associated factors influence PIKKs activity.
Telomerase and telomeres are attractive targets for cancer
therapies and have been extensively explored to this end (2).
Inhibition of telomerase by antisense strategies or a dominant
negative hTERT protein leads to the expected telomere short-
ening, although the growth inhibition induced by this mecha-
nism requires a long lag period due to the number of cell divi-
sions required for telomeres to become substantially shortened
to induce growth arrest (44, 45). Recently, some studies have
reported rapid cytotoxic responses of cancer cell lines in
response to low levels of hTERT and hTR. A novel telomere-
independent growth inhibitory response pathway was pro-
posed (46, 47). Here, we investigated the effects exerted by hTR
on the cellular growth and checkpoint controls and uncovered
a novel, telomerase-independent, function of hTR to counter-
balance the activity of endogenous ATR.
EXPERIMENTAL PROCEDURES
Materials and Antibodies—UV radiation was performed
with a Stratalinker (Stratagene), and ionizing irradiation was
performed with a 2 � 415-Ci137Cs source. Prior to UV radia-
tion, medium was reserved, and cells were washed with phos-
phate buffered saline (PBS). Antibodies used in this study were
directed against cdk4 (C-22), p53 (DO1) (Santa Cruz Biotech-
nology), phospho-Ser-15 p53, phospho-Ser-317 Chk1, phos-
pho-T68 Chk2 (Cell Signaling), FLAG (M2, Sigma), �-H2AX
(Ser-139, Upstate Biotechnology), and ATR (ab2905, Abcam).
Constructs—hTR knockdown constructs were cloned in
pSuper, pRetroSuper(pRS)-Hygro (48), and pRS-GFP (49). The
sequences used were as follows: hTRkd#1, GTCTAACCCTA-
ACTGAGAAGG; hTRkd2, CCGTTCATTCTAGAGCAAAC;
hTRkd3, GAGTTGGGCTCTGTCAGCC. The CMV-hTR
expression construct was cloned by PCR in pcDNA3.1 vector
(Invitrogen) to contain 149 nucleotides downstream of the full-
length hTR for proper processing; H/ACA box snoRNA con-
structs were also cloned into this vector. pRS-p53kd and
pRS-Rb were described previously (49). ATRkd sequences used
were as follows: #1, GACGGTGTGCTCATGCGGC; #2, CCT-
GATGGAGTGGCCGGAG; we used a combination of the two
constructs cloned in pSuper. We cloned the ATR cDNA from
the pBJ5.1-Flag-ATR (a kind gift from Professor Steve Jackson)
vector into the pZome1N vector (Cellzome) downstream of the
TAP tag (50). The GST-p53 (amino acids 1–101) construct was
cloned by PCR into pGEX-1N (Amrad). pTRI-GAPDHand -cy-
clophilin constructs for the RNase protection assay (RPA) were
fromAmbion, and the hTR RPA vector was cloned by PCR into
pTRI (Ambion) from nucleotides 105–370 in reverse
orientation.
Cell Culture, Retroviral Transduction, and Transfection—All
cells described here were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% heat-inactivated fetal
calf serum in 5% CO2 at 37 °C. BJ cells were transduced at pop-
ulation doubling 35. The generation of BJ-tert cells has been
described previously (49); GM847 cells were a kind gift from
Professor Batsheva Kerem. MCF7, U2OS, and TIG3 cell lines
expressing the ecotropic receptor were infected with ecotropic
retroviral supernatants as described previously (48) to generate
polyclonal pools of cells. Except for kinase assays, transfection
was done by electroporation as described previously (51). For
kinase assays, HEK293, U2OS, andMCF7 cells were transiently
transfected using calcium phosphate precipitation.
Western Blotting, Cell Cycle Profile Analysis, andCompetitive
Growth Assays—ForWestern blot analysis, whole-cell extracts
were prepared and separated on 10% SDS-PAGE gels, and ATR
immunoblots were separated on 5% SDS-PAGE gels and trans-
ferred to Immobilon-P membranes (Milipore). Western blots
were developed with Supersignal (Pierce), and densitometric
quantitation of Western blots was performed with Aida 3.40
software (Raytek, Sheffield, UK). Cell cycle profile analysis was
performed as described before byDuursma et al. (52). For com-
petitive growth assays, cellswere infectedwith pRS-GFP-hTRkd
or pRS-GFP retrovirus and allowed to recover for 4 days; the
initial percentage of GFP-positive cells varied between 15 and
50%. The cells were analyzed by flow cytometry with the
CellQuest program (BD Bioscience).
Telomerase Activity Assays, Quantitative RT-PCR, and
RNase Protection Assays—MCF7 extracts were assayed for
telomerase activity using a PCR-based telomeric repeat ampli-
fication protocol (TRAP) assay (53). For RT-PCR, cDNA was
transcribed using SuperSCRIPT III (Invitrogen) with random
hexamers following the manufacturer’s instructions. Quantita-
tive PCR was performed with a SYBR Green master mix
(Applied Biosystems), and the samples were amplified and ana-
lyzed by an ABI-prism 7000 sequence detection system
(Applied Biosystems). Primers for OAS1 (2�5�-oligoadenylate
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synthetase) were described before (54), andCt values were nor-
malized for �-actin. RPAs were performed using the HybSpeed
RPA andMAXIscript kits fromAmbion according tomanufac-
turer’s instructions. We used 5–8 �g of RNA per reaction. In
vitro transcription of pTRI-hTR yielded an RNA of 300 nucle-
otides, 265 nucleotides of which are complementary to hTR.
Immunoprecipitation Kinase Assays—To determine ATR
activity, TAP-ATR was immunoprecipitated from extracts of
transfected HEK293, MCF7, or U2OS cells using rabbit IgG-
Sepharose (Sigma). Prior to immunoprecipitation, cells were
UV irradiated with either 80 or 20 J/m2 or mock treated. Beads
were washed three times with ELB lysis buffer (125 mM NaCl,
50 mM Hepes, pH 7.5, 0.1% Nonidet P-40, 0.5% Tween 20, 0.5
mM NaOV, 2 mM �-glycerophosphate, and protease inhibitor
mixture (Roche Applied Science)) and ATR was cleaved from
the beads by addition of recombinant TEV protease (Invitro-
gen) for 2 h at 8 °C according to manufacturer’s instructions.
The substrate, GST-p53-(1–101) bound to glutathione beads
(Amersham Biosciences), was washed three times with kinase
buffer (20 mM HEPES (pH 7.5), 50 mM NaCl, 10 mMMgCl2, 10
mM MnCl2, 1 mM dithiothreitol, 0.5 mM NaOV, and 2 mM
�-glycerophosphate). Reactions were carried out in a 50-�l vol-
ume of kinase buffer with cleaved ATR, 10 �g of GST-p53-(1–
101), 10 �Ci of [�-32P]ATP (500 mCi/mmol, Amersham Bio-
sciences) at 30 °C for 15 min. In samples with RNase A, 0.5 �g
was added to the kinase reaction prior to the addition of the
substrate; we added 1�g of in vitro transcribed hTR or H/ACA
snoRNA to the indicated samples, which was produced from
linearized CMV-hTR/snoRNA plasmid with a MAXIscript in
vitro transcription kit (Ambion) according to manufacturer’s
instructions. The beads with GST-p53-(1–101) were then
extensively washed and subjected to 10% SDS-PAGE, and the
gel was dried, stained with Coomassie Blue, and exposed to a
phospho imager screen for quantitation on a Basreader 3000
(Fuji) with Aida 3.40 software (Raytek, Sheffield, UK).
Immunofluorescence,Mitotic Entry, and Fragile Site Assays—
MCF7 cells were transfected by electroporation (�90% effi-
ciency) with the indicated constructs. Cells were washed with
PBS, fixed, permeabilized in 4% formaldehyde and 0.2% Triton
X-100, and washed with PBS containing 0.05% saponin. Slides
were blocked with 10% normal goat serum in PBS with 0.05%
saponin. Cells were stained with antibody directed against
phosphorylated H2AX; fluorescein isothiocyanate-conjugated
goat anti-mouse antibodies were used as secondary antibodies.
Images were recorded with a Leica TCS SP2-AOBS (Leica
Microsystems, Heidelberg, Germany) confocal system. For
counting mitotic entry, after 72 h, transfectedMCF7 cells were
treated with 5 Gy ionizing radiation (IR) or mock treated and
incubated with nocodazole (0.25 �g/ml) for 24 h. Cells were
fixed with 3.7% formaldehyde, permeabilized for 5 min with
0.1% Triton X-100 (Sigma) and stained with Hoechst. Mitotic
cells were scored double blind with a Zeiss RS III microscope.
For each sample, 600 cells were counted. For fragile site assays,
cells were grown on coverslips, and common fragile sites were
induced by growing the cells inM-199medium in the presence
of 0.4 �M aphidicolin and 0.5% ethanol, for 24 h prior to the
fixation of chromosomes by standard procedures. Images were
obtained with a Zeiss Axiovert 100 TV inverted microscope
controlled by SmartCapture2 software. For each sample, 400
chromosomes were counted double blind.
RESULTS
Inhibition of hTR Expression Induces a Rapid Cellular
GrowthArrest—To inhibit hTR expressionwe designed shRNA
constructs to target sequences in different regions of the hTR
molecule. We aimed our constructs to three distinct single-
stranded (loops) regions of the hTR molecule, as predicted by
its very strong and conserved secondary structure (19) (Fig. 1A).
To assess the efficacy of inhibition of hTR expression, we trans-
fectedMCF7 breast carcinoma cells with the shRNAconstructs
or a vector control. We used RPA with RNA probes partially
complementary to hTR or cyclophilin control to assess hTR
RNA levels in cell extracts (Fig. 1B). Quantitative analysis
revealed that hTRkd#1 and hTRkd#2 reduced the levels of
endogenous hTR to 19 and 67%, respectively, whereas no hTR
reduction was seen by hTRkd#3. U2OS osteosarcoma cells,
which lack expression of hTR and hTERT but maintain their
telomeres by ALT (55, 56), were used as a control. Indeed, no
hTR expression was observed in U2OS cells, which could be
re-expressed through transfection of a CMV-hTR plasmid (Fig.
1B). We also verified the extent of hTR knockdown in nuclear
and cytoplasmic extracts to exclude knockdown of hTR only in
cytoplasmic fractions (supplemental Figs. S1 and S2).We found
that hTR resides mainly in the nucleus, and upon expression of
hTRkd#1, hTR levels in both nuclear and cytoplasmic fractions
were dramatically decreased. To assess the effects of inhibition
of hTR on telomerase activity we performed a TRAP assay with
extracts ofMCF7 cells transfectedwith the hTRkd constructs or
control plasmid. As expected we found almost no telomerase
activity in hTRkd#1-transfected cells, and hTRkd#2 gave amod-
erate reduction, whereas hTRkd#3 did not inhibit telomerase
activity.
To investigate the effect of hTR knockdown on cell growth,
we transfectedMCF7 cells with the three hTRkd constructs and
analyzed them 2 days later by flow cytometry. Surprisingly, the
introduction of hTRkd#1 shRNA vector induced a cell cycle
arrest at both G1 and G2 (Fig. 1D), whereas the hTRkd#2 arrest
was reduced, and hTRkd#3 had no effect (data not shown). To
verify this result we tested additional hTR-targeting siRNAs
with RPA and flow cytometric analysis in MCF7 cells (supple-
mental Figs. S3 and S4). Transfection of these siRNAs sup-
pressed the expression of hTR and elicited a comparable rapid
growth arrest as hTRkd#1. Consistent with these results, the
long term survival of hTRkd#1-transfectedMCF7 cells (Fig. 1E)
and virally transduced hTRkd#1-MCF7 cells (Fig. 1F) wasmark-
edly impaired. The observed inhibition of proliferation by
hTRkd#1 was not a consequence of non-relevant toxicity as this
vector induced no interferon response (Fig. 1G). Furthermore,
no anti-proliferative response was seen in U2OS cells, as these
express no hTR (Fig. 1B). Both by flow cytometry as well as by
competitive growth assays, hTRkd#1 was not toxic to U2OS
cells but was highly toxic in MCF7 cells (Fig. 1, H and I).
hTRkd#2 inhibited growth ofMCF7 cells to intermediate levels,
reflecting its capacity to knockdown hTR. These results are
further strengthened by the use of additional siRNA reagents
targeting hTR (supplemental Figs. S2 and S3). This shows that
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the growth inhibition triggered by the knockdown of hTR in
MCF7 cells is dependent on the level of knockdownof hTR.The
same anti-proliferative effect of hTRkd#1 was also obtained in
other human cell lines, such as HaCaT immortalized keratino-
cytes, HeLa cervical carcinoma cells, and T47D mammary car-
cinoma cells (supplemental Fig. S5). Altogether, these results
show that inhibition of hTR expression by shRNAelicits a rapid
anti-proliferative response in human cells.
Due to the continuous rapid proliferation of cancer cell lines
and emergence of critically short telomeres, the inhibition of
hTR expression may induce a stress response. To examine this,
we studied hTR inhibition in young primary human cells (pas-
sage 35) that express hTR and contain sufficiently long
telomeres to maintain proliferation for 30–40 additional pas-
sages. Also in these cells, suppression of hTR inhibited cell
growth depending on the level of hTR knockdown (Fig. 1J).
Altogether, our results indicate that inhibition of hTR expres-
sion induces a cell cycle arrest, which is not caused by critically
short telomeres.
Cell Cycle Arrest Induced by Inhibition of hTR Expression
Requires p53 and CHK1—To elucidate the response of cells to
reduced hTR levels we monitored p53 levels, a tumor suppres-
sor and a major transducer of cell cycle arrest in response to
oncogenic and genotoxic stresses. We transfected MCF7 cells
with p53kd (57) and hTRkd or control constructs and found p53
protein levels to be three times higher in the hTRkd#1-trans-
fected cells comparedwith controls (Fig. 2A). This suggests that
the growth arrest observed in hTRkd cells involves p53 activa-
FIGURE 1. Reduction of telomerase activity and rapid growth inhibition by reduction of hTR expression. A, schematic representation of the hTR RNA.
Boxed regions correspond to targeted sequences by shRNAs 1, 2, and 3, and the template sequence is shown in a closed box. B, RPA was used to detect the levels
of hTR and the control cyclophilin. The full-length probes and protected fragments are indicated, and 10% of the input probe was loaded on the gel.
Quantification was performed by densitometry. C, a TRAP assay was performed to detect telomerase activity in extracts of MCF7 cells transfected with the
indicated constructs. D, MCF7 cells were transfected with hTRkd#1 or vector constructs and subjected to flow cytometric analysis. The percentages of cells in G1,
S, and G2 phases are shown. S.D. is from three independent experiments. E, a colony growth assay of MCF7 cells transfected with the hTR knockdown constructs
or a vector control. Cells were selected with hygromycin for 10 days and stained with Coomassie Blue. F, colony growth assay of virally transduced MCF7 cells.
G, MCF7 cells were transfected with indicated constructs, and RNA was extracted after 3 days. OAS1 mRNA levels were measured by quantitative RT-PCR, shown
relative to �-actin mRNA. S.D. is from three independent experiments. H, flow cytometry is the same as in D only that U2OS cells were used. I, competitive
growth assay the U2OS and MCF7 cells were transduced with indicated pRS-GFP constructs. Fluorescence was monitored by flow cytometry at the indicated
timepoints after transduction. J, competitive growth assay performed on transduced primary BJ fibroblasts as in I. ctr, control.
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tion. To test this directly, we performed competitive growth
assays using MCF7-p53kd and MCF7 control cells that were
virally transduced with the GFP-hTRkd#1 or GFP control vec-
tor. Fig. 2B shows that loss of p53 expression, which completely
abrogates a DNA damage response (57), only partially rescued
the arrest induced by loss of hTR. A similar result was obtained
in TIG3 primary fibroblasts (supplemental Fig. S6).
Activation of p53 can be a result of activation of the kinases
ATM and ATR, which in turn activate CHK2 and CHK1,
respectively (40). To examine whether the cell cycle arrest
induced by the loss of hTR depends on the combination of p53
and CHK1, we performed a GFP competition assay with BJ and
BJ-p53kd cells in the presence of theCHK1 inhibitorUCN-01 or
vehicle as control (58, 59). Fig. 2C shows that hTRkd#1-induced
toxicity was almost completely abrogated when both p53
expression and CHK1 activity were inhibited. Similar results
were obtained in MCF7 cells (data not shown). These results
indicate that loss of hTR activates both p53 and CHK1 to elicit
a rapid cell cycle arrest, indicating the involvement of ATR in
this process.
FIGURE 1—continued
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hTR Inhibits ATR Activity—Our results suggest an inverse
correlation between hTR levels and ATR activity. Reduction in
hTR levels induces p53 andCHK1, twomain substrates of ATR.
To examine this further, we askedwhether the presence of hTR
inhibitsATRactivity. ATR is activated byDNAdamage assaults
such as UV radiation, thereby inducing the phosphorylation of
p53S15 and CHK1S317, respectively (60–62). To test the role of
hTR in this process we used U2OS cells, which express no hTR,
and ectopically expressed hTR (Fig. 1A). Importantly, the levels
of expressed hTR in U2OS cells were lower than the endoge-
nous levels observed in MCF7 cells and could not complement
for telomerase activity due to the lack of hTERT expression in
these cells (data not shown).We irradiated hTR expressing and
control cells with UV and followed the phosphorylation kinet-
ics of CHK1S317and p53S15 in time. Interestingly, upon radia-
tion, the phosphorylations of both CHK1S317 and p53S15 were
severely attenuated in U2OS cells expressing hTR (Fig. 3A). In
addition, p53 stabilitywas not increased upon radiation in hTR-
expressing cells as compared with control cells.
Since U2OS cells express neither hTR nor hTERT, it
seems that hTR inhibits ATR in an hTERT independent
manner. To examine this issue we aimed at testing the effects
of hTR knockdown in a telomerase negative cell line. There-
fore, we used GM847 human fibroblasts; these cells elongate
telomeres by the ALT mechanism and express hTR but not
hTERT (12). We transfected cells with the hTRkd#1 con-
struct, treated the cells with UV radiation (3 J/m2), and mon-
itored phosphorylation of CHK1S317 and p53S15 using immu-
noblot analysis. We found that reduction in endogenous
hTR levels triggered CHK1S317 and p53S15 phosphorylation,
as well as p53 stabilization, indicating ATR activation (Fig.
3B, time 0�). To exclude off target
effects of hTR knockdown, we
tested additional siRNAs that
inhibit hTR expression. We found
also those to elicit a rapid cell cycle
arrest and to trigger CHK1S317 and
p53S15 phosphorylation and p53
stabilization (supplemental Figs.
S3, S4, and S7). This strongly sug-
gests that inhibition of hTR causes
the reduction in cell proliferation
capacity and activation of DNA
damage checkpoints. Interesting-
ly, hTR depletion activated the
DNA damage response to almost
full extent as treating hTRkd cells
with UV resulted in only a slight
activation of p53 and CHK1 com-
pared with control cells (3B).
Altogether, these results suggest
that endogenous levels of
hTR are functioning to balance
ATR activity, a function that is
telomerase-independent.
To study the effects of hTR on
ATR kinase activity in more detail,
we used an ATR construct with a
TAP (tandem affinity purification) tag containing a TEV prote-
ase cleavage site (50). We transfected HEK293 cells with TAP-
ATR or TAP control, purified them from extracts by immuno-
precipitation using IgG beads (Fig. 3C, lanes B), and released
using TEV protease (lanes S). We studied effects of hTR on
ATR-kinase activity using GST-coupled p53 (amino acids
1–101) as its substrate. Fig. 3D shows that our purified ATR
could phosphorylate p53, as expected (lane ctrl). When hTR is
incubatedwithATR a clear and potent decrease inATR activity
is observed (lane hTR). As control we used a truncated hTR
RNA encompassing the first 211 nucleotides of hTR (lane hTR
211). This truncated hTR inhibited ATR activity in vitro to a
lesser extent than the full-length hTR, indicating for the speci-
ficity of the hTR effect. Additionally, since hTR contains a
H/ACA box (2, 19), we tested related H/ACA snoRNAs for
their ability to influence ATR kinase activity. We found that
these RNAs hardly affect ATR kinase activity, indicating that
the inhibition of ATR by hTR is specific (supplemental Fig. S8).
As HEK293 cells express hTR, we reasoned that addition of
RNase should increase ATR activity. Indeed, when RNase was
added toATR, or toATR and hTR, kinase activity was relatively
increased. These results indicate that ATR kinase activity is
inhibited by hTR in vitro.
To further examine the effects of hTR onATR kinase activity
we performed kinase assays with TAP-ATR in U2OS cells that
lack hTR expression. Cells were transfected with TAP-ATR or
TAP-control plasmid and cotransfected with CMV-hTR or
control plasmids. Three days after transfection, cells were
either left untreated or UV irradiated to activate ATR, and sub-
sequently ATRwas purified and subjected to a kinase assay. Fig.
3E shows that exogenous ATR is active in mock treated U2OS
FIGURE 2. Chk1 and p53 are required for induction of the hTRkd-mediated cell cycle arrest. A, MCF7 cells
were transfected with indicated constructs and subjected to immunoblot analysis to detect p53 and the
control CDK4. Band intensity was calculated by densitometry. B, MCF7 cells were transduced with p53kd or
control vector, drug-selected, and transduced with pRS-GFP control and hTRkd#1-GFP. Competitive growth
assays were performed as described in the legend to Fig. 1I. C, competitive growth assays with BJ cells as in B.
Cells were either treated with UCN-01 (10 nM, dashed lines) or with vehicle (dimethyl sulfoxide (DMSO), solid
lines).
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cells and is slightly activated when cells are irradiated (lanes 1
and 2). However, when hTR is coexpressed with TAP-ATR,
ATR activity is markedly decreased, almost to the levels of the
control transfection (lanes 5 and 6).
Next, we performed a similar exper-
iment using MCF7 cells that, unlike
U2OS cells, express hTR. Fig. 3F
shows ATR activation upon UV
radiation (lanes 1–4). However,
reduction in hTR levels induced
ATR activity already in the
untreated cells (lane 5), which was
not further activated by UV at this
time point after treatment (lane 6).
As shown above, ATR signaling is
activated when hTR is depleted.
Our results so far suggest that the
effect of hTR on ATR activity is
direct. ATR is normally activated by
DNA damage, upon which it acti-
vates p53 and CHK1 but also phos-
phorylates histone H2AX (40).
Phosphorylated H2AX (�-H2AX)
colocalizes with other factors, such
as p53BP1, MRE11, and SMC1, to
foci marking sites of DNA damage,
thereby facilitating the assembly of
checkpoint and DNA repair factors
(40). Such foci are also found at dys-
functional telomeres (5, 37). To test
whether hTR depletion acts directly
through ATR or indirectly via
induction of DNA damage, we
stained hTRkd cells for �-H2AX
foci. MCF7 cells were transfected
with hTRkd or vector control or irra-
diated as positive control. While IR
generated �-H2AX foci, no increase
in foci formation above control was
observed in cells expressing hTRkd
shRNA, hTRkd siRNA (data not
shown) (Fig. 3G). A similar result
was obtained previously with 53BP1
foci in LOX cells (46). Thus, we
found no evidence of DNA damage
in cells depleted of hTR supporting
the notion that the effects of hTR on
ATR are direct. Altogether, our
results show that the expression of
hTR influences ATR kinase activity
in vivo.
Partial Abrogation of the G2/M
Checkpoint and Enhanced Appear-
ance of Fragile Sites by hTR
Expression—ATR has been shown
to be involved in the radiation-in-
duced G2/M phase checkpoint in
eukaryotic cells as it prevents
mitotic entry of cells mainly in the late phase of the response to
IR and cooperates with ATM in the early phase of the response
(42). Since our results show that hTR inhibits ATR, we studied
FIGURE 3. hTR inhibits ATR kinase activity. A, U2OS cells were transfected with the hTRkd or control, irradiated
after 3 days with 3 J/m2 UV, and harvested at the indicated time points. Whole cell extracts were immuno-
blotted to detect CHK1S317 phosphorylation, p53S15 phosphorylation, p53, and CDK4 as a loading control. B,
GM847 fibroblasts were transfected with hTRkd or control and treated as in A. C, HEK293 cells were transfected
with TAP-ctr or TAP-ATR and immunoprecipitated with IgG. TAP-ATR was cleaved with TEV protease, and beads
(B) and supernatant (S) were immunoblotted to detect ATR. WB, Western blot. D, kinase assay performed with
immunoprecipitation and TEV cleaved TAP-ATR from HEK293 cells with GST-p53 (residues 1–101) as a sub-
strate. Cleaved ATR was split, and hTR, RNase, and mock were added prior to kinase reaction. Samples were
separated by 10% SDS-PAGE and stained with Coomassie Blue to detect GST-p53 protein, and autoradiogra-
phy was performed to detect kinase activity. Band intensities were measured by densitometry. E, U2OS cells
were transfected with the indicated constructs and kinase assays were performed as in B. F, MCF7 cells were
transfected with the indicated constructs, and kinase assays were performed as in B. G, immunofluorescence
images of MCF7 cells transfected with hTRkd#1, vector, or control irradiated cells (5 Gy IR), stained with �-H2AX
antibody. Nuclei are stained with DAPI (blue). Pictures were made with �200 magnification. vec, vector.
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the effects of hTR expression on the G2/M checkpoint. We
monitored mitotic entry of MCF7 cells in response to IR as a
measure for the number of cells able to arrest in G2/M. We
transfectedMCF7 cells with CMV-hTR and as controls ATRkd,
p53kd, or CMV-control constructs (for validation of the ATRkd
constructs, see supplemental Fig. S9). Three days later we irra-
diated cells with 5 Gy IR and treated the cells with nocodazole
to inhibit progression of the cell cycle in mitosis. Cells were
then fixed, stainedwithHoechst andmitotic cells were counted
(Fig. 4A). While we found no difference in the accumulation of
mitotic cells in unirradiated controls, hTR overexpression,
ATRkd and p53kd, showed a partial override of the G2/M arrest.
In contrast, cells expressing a truncated form of hTR (hTR211)
behaved as control cells. Notably, hTR levels are only moder-
ately increased in MCF7 cells upon expression of CMV-hTR (a
35% increase, supplemental Fig. S10). Altogether, these results
indicate that an increase in hTR levels impairs ATR-mediated
DNA damage responses in a manner similar to those induced
by loss of ATR.
To further investigate whether hTR expression perturbs
ATR function, we studied fragile sites stability in U2OS cells.
Common fragile sites are specific chromosomal loci that appear
as constrictions, gaps, or breaks on metaphase chromosomes
from cells that have been exposed to partial inhibition of DNA
replication (63). Addition of low levels of the DNA polymerase
inhibitor aphidicolin to cells in culture has been shown to
induce fragile sites. ATR recognizes stalled and collapsed DNA
replication forks and activates their repair and the restarting of
replication. Fragile sites are believed to be expressed when
stalled forks escape the ATR replication surveillance (64). We
transfected U2OS cells with CMV-hTR, ATRkd, or CMV-ctrl,
and treated the cells for 24 h with aphidicolin. Chromosomes
were fixed, stained, and dropped onto slides to count chromo-
somes and fragile sites.Upon inhibition of replication,we found
fragile sites instability in control cells, which was exacerbated
by either loss of ATR or expression of hTR (Fig. 4B). Quantifi-
cation of the frequency of fragile sites expression showed a
2-fold increase in the number of fragile sites in the hTR express-
FIGURE 4. hTR partially abrogates the G2/M checkpoint and enhances the expression of fragile sites. A, MCF7 cells were transfected with the indicated
constructs irradiated with 5 Gy IR or mock treated 3 days later and incubated with nocodazole. Twenty-our hours later, cells were fixed and stained with
Hoechst, and mitotic entry was scored. S.D. from three independent experiments is shown. B, the expression of fragile sites in U2OS cells transfected with the
indicated constructs. Pictures were made with �1000 magnification. C, quantification of the expression of fragile sites in U2OS cells as shown in Fig. 4B. The
number of fragile sites expressed in 400 chromosomes is shown; data are representative of three independent experiments.
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ing cells as well as in the ATRkd cells (Fig. 4C). As maintaining
low levels of fragile site expression are a prime function of ATR,
our results indicate that hTR inhibits ATR activity. Altogether,
these results show that hTR inhibits ATR activity to a level
sufficient to impair different ATR-mediated DNA-damage
checkpoint responses, implying a novel function for hTR.
hTRUp-regulation followingUVRadiation—Wenext set out
to elucidate the function of the inhibitory effect of hTRonATR.
To this end, we investigated whether stimuli that activate ATR
also influence the expression of hTR. We treated primary BJ
fibroblasts and BJ cells overexpressing hTERT (BJ-ET) with 3
J/m2 UV light and extracted RNA at several time points after
radiation. Subsequently, we subjected these RNA extracts to
RPAwith an hTR probe and cyclophilin orGAPDHas controls.
Fig. 5A shows that following UV radiation, but not IR (4 Gy),
hTR levels increase in parent BJ cells. In BJ-ET cells, as pub-
lished previously (30), higher levels of hTR are detected in
untreated cells. Still, a clear up-regulation of hTR levels follow-
ing UV treatment is detected (Fig. 5A). The increase in hTR
level following UV radiation was not due to a cell cycle arrest of
the cells, as hTR levels did not increase in IR-treated cells (Fig.
5, A and B).
Next, we characterized the response of hTR to UV. First, we
examined dependence on hTERT by using GM847 cells that
express hTR but not hTERT. Also in these cells hTR was up-
regulated in response to UV radiation (Fig. 5C), indicating
that the up-regulation of hTR is independent of hTERT. Sec-
ond, we investigated whether the up-regulation of hTR is
dependent upon p53 or CHK1 activity by using BJ-p53kd
cells and cells treated with UCN-01. In these experiments,
hTR was still up-regulated in response to UV radiation when
compared with control time points, indicating that p53 and
CHK1 are not involved in the up-regulation of hTR in
response to UV radiation (Fig. 5D). Collectively, we uncov-
ered that hTR is specifically up-regulated in response to low
levels of UV radiation. This up-regulation is not observed in
response to ionizing radiation and is independent of p53,
CHK1, and hTERT.
FIGURE 5. Up-regulation of hTR levels following UV radiation. A, RPA performed on extracts from BJ cells and BJ cells immortalized with hTERT irradiated
with 3 J/m2 UV or 4 Gy ionizing radiation. Cells were harvested after irradiation at the indicated time points, and quantification was performed by densitometry.
B, quantification of RPAs on extracts of BJ cells irradiated with either 3 J/m2 UV or 4Gy ionizing radiation. Samples were harvested at indicated time points after
irradiation. S.D. is from three independent experiments; band intensities were quantified by densitometry. C, RPA performed on extracts of GM847 cells
irradiated with 3 J/m2 UV as in A. D, quantification of RPAs on extracts of the indicated cells irradiated with 3 J/m2 UV. UCN-01 was added to a final concentration
of 100 nM 1 h prior to irradiation. S.D. is from three independent experiments. Ctr, control; Vec, vector.
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DISCUSSION
We have identified a causative genetic interaction between
the hTR and the checkpoint kinase ATR. Ectopic expression of
hTR inhibits ATR, while reduction in hTR levels stimulates
ATR activity. This interaction is independent of telomerase
activity and telomere length as it was observed in cells lacking
hTERT and in young primary human cells with telomeres long
enough to allow proliferation for at least 20 to 30 passages.
Interestingly, the effect of hTR on ATR activity was strong
enough to influence cellular pathways. Inhibition of hTR
expression elicited a p53/CHK1-dependent cell cycle arrest in
the absence of apparent DNA damage, while increased expres-
sion of hTR caused defects in ATR-dependent checkpoints,
such as override of theG2/Marrest in response toDNAdamage
and the enhanced induction of fragile sites. These effects are
specific since the hTR knockdowns do not elicit any interferon
response and phenotypically depend on the endogenous
expression of hTR, and the effectswere observedwithmild (less
than 50% above endogenous) overexpression of hTR. Notably,
such a mild increase in hTR expression is also observed when
cells are UV irradiated, indicating that such an increase is suf-
ficient to impair ATR dependent checkpoints (Fig. 5B). An
important observation is that both the inhibition of ATR activ-
ity by hTR and the up-regulation of hTR by UV damage are
independent of hTERT. Activation of ATR in response to UV is
very rapid, occurring within minutes (Fig. 3, A and B), whereas
the increase in hTR levels takes several hours and is comparable
with the increase seen inMCF7 cells following hTRoverexpres-
sion resulting in checkpoint suppression (Fig. 5B and supple-
mental Fig. S10). These kinetics are consistent with the idea
that cell cycle inhibition has to be rapidwhile the recovery takes
several hours, depending on the extent of damage. Based on
these findings, our results imply a model where up-regulation
of hTR in response to UV constitutes a feedback loop bringing
down ATR activity to reinitiate cell cycle progression (Fig. 6).
Our results show that reduction in endogenous hTR levels
leads toATRactivationwithout the induction of apparentDNA
damage. These results prompted us to investigatewhetherATR
and hTR interact directly. Interestingly, homologues of ATR in
yeast andArabidopsis are involved in telomeremetabolism and
in yeast Mec1p (ATR homolog) associates with telomeres (38,
43, 65, 66).We were unable to demonstrate a direct interaction
of ATR and hTR. Thus, our further experiments should eluci-
date by which mechanism hTR influences ATR activity. ATR
was previously shown to be involved in signaling pathways acti-
vated by replication arrest andDNAdamage assault in cells in S
and G2 phases (42, 62, 67). Common fragile sites are known to
be susceptible hotspots to chromosomal breakage, rearrange-
ment, and deletion and have been implicated in the genomic
instability frequently observed in cancer (63). ATR is involved
inmaintaining the stability of fragile sites, as its inhibition leads
to an increase in the expression of fragile sites (64).Our findings
demonstrate that hTR expression induces the appearance of
fragile sites to an extent similar to ATRkd, thus suggesting that
an increase in hTR levels can lead to genomic instability. Sup-
porting this conclusion is our observation that an increase in
hTR levels weakens the G2/M arrest, a checkpoint controlled
also byATR.These results also suggest that hTR expression can
lead to reduced fidelity of the ATR-dependent checkpoints and
therefore to increased genomic instability.
Recently, the group of Elizabeth Blackburn has shown that
reduction in hTR levels in cancer cells elicits a rapid anti-pro-
liferative response (46). However, when comparing hTRknock-
down in HCT116 cells with p53-null HCT116 cells they con-
clude that the growth inhibitory response is p53 independent.
Our results, on the other hand, indicate a partial dependence on
p53 function. One obvious reason for this discrepancy can be
that Li et al. (46) based their conclusion on results obtained
with twoHCT116 cell lines with very different growth rates, the
p53-null cell line grows an order of magnitude slower than the
wild type cell line, making a comparison between growth inhi-
bitions very difficult. In contrast, we used in our study primary
human BJ and TIG3 fibroblasts as well as MCF7 breast carci-
noma cells and directly compared them with corresponding
knockdown p53 cells. Furthermore, our results clearly indicate
that the regulation of ATR by hTR is sufficient to affect cellular
pathways.
Our results seem to contrast the findings that mTR�/� mice
have no obvious phenotype in the first generations (34). The
fact that first generation mTR�/� mice are less prone to devel-
oping skin tumors upon chemical carcinogenesis can be
explained bymild activation of someDNAdamage checkpoints
induced by loss of mTR (35). Whether this effect is mediated
through ATR remains to be elucidated. Additionally, there are
several differences betweenmouse and human telomere home-
ostasis that complicate extending findings from mouse models
to the human setting. First, murine cells have extremely long
and hypervariable telomeres, and telomerase activity is detect-
able in most somatic tissues (68, 69). Second, although telom-
erase is activated and mTR is up-regulated in vivo in several
mouse tumor models, it appears not to be required for growth
during the cell divisions necessary for tumor formation, sug-
gesting that mTR and/or telomerase have additional functions
to telomere extension (32–34). In addition, telomere dysfunc-
FIGURE 6. Model for the hTR-mediated negative feedback loop on ATR
activity in response to UV. Low levels of UV radiation activate the ATR kinase
early in the UV response, which phosphorylates downstream targets, among
which are p53 and Chk1, leading to a cell cycle arrest and induction of DNA
repair. Independently, hTR levels are increased by a yet unknown mechanism.
These increased hTR levels inhibit ATR at a later stage.
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tion in mice appears to be solely dependent on p53, whereas in
human cells the pRB pathway is also activated (70, 71). Third,
while RNA interference causes a fast reduction in hTR levels,
knock-out of telomerase RNA in germ line cells may allow for
compensation events to occur (36). Thus, our results may indi-
cate for either a difference in telomerase RNA biology between
mice andmen or to differences inmethods used. Further exper-
imentswithmurine cells are required to establishwhethermTR
also regulates ATR.
Last, our results may provide an explanation why in the vast
majority of somatic human cells, hTR is ubiquitously expressed,
whereas both hTERTand telomerase activity aremostly absent.
hTR regulates DNA damage pathways in a telomerase and
hTERT-independent manner. Our results, thus, can explain
observations suggesting that hTR plays a role in the initiation of
tumorigenicity and that it is frequently up-regulated in human
cancer cell lines (23–33).
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Legends to supplementary Figures 
Fig. S1. hTR knockdown in MCF7 cytoplasmic and nuclear extracts. RPA performed on equal 
amounts of cytosolic and nuclear extracts from MCF cells transfected with either pS-hTRkd#1 or 
control pS (t= total lysate; c= cytoplasmic extract; n=nuclear extract). Cells were harvested 4 days 
after transfection cellular fractionation was performed using NE-PER kit (Pierce) according to 
manufacturer's instructions.  
FIG. S2. A control immunoblot performed with 50 ug of cytosolic and nuclear protein extracts 
obtained from the same cell populations described in S1.  
Fig. S3. Multiple siRNAs inhibit hTR expression. RPA performed on extracts from MCF cells 
transfected with pS, hTRkd#1, and three different siRNAs targeting the hTR regions indicated (the 
siRNAs targeting nucleotides 44-62 and 165-14 of hTR were the same as used by Li et al. (ref. 46)). 
Cells were harvested 4 days after transfection. Quantification was performed by densitometry. 
Fig. S4. Inhibition of hTR expression triggers rapid growth inhibition. MCF cells were 
transfected with hTRkd#1, vector constructs and indicated siRNAs and subjected to flow cytometric 
analysis. The percentages of cells in G1-, S- and G2-phases are shown. SD is from 3 independent 
experiments.
Fig. S5. Rapid growth inhibition by inhibition of hTR expression. Competitive growth assay of 
Hacat, HeLa, and T4D cell lines. Cells were transduced hTRkd#1GFP construct and fluorescence was 
monitored by flow cytometry at the indicated timepoints after transduction. 
Fig. S6. Induction of the cell cycle arrest mediated by hTRkd in TIG3 fibroblasts is partially 
dependent on p53. TIG3 cells were transduced with p53kd or control vector, drug selected and 
subsequently transduced with hTRkd#1-GFP, or pRS-GFP control. Competitive growth assays were 
performed as described in Fig. S4. 
Fig. S7. Inhibition of hTR expression triggers activation of ATR downstream targets. GM4 
fibroblasts were transfected with hTRkd#1, control pS and the indicated siRNAs. Whole cell extracts 
were immunoblotted to detect CHK1S31 phosphorylation, p53S15 phosphorylation, p53, and CDK4 as a 
loading control.
Fig. S8. Inhibition of ATR kinase activity is specific for hTR.  Kinase assay performed with IP and 
TEV cleaved TAP-ATR from HEK23 cells with GST-p53 (residues 1-101) as a substrate.  Cleaved 
ATR was split and mock, hTR, hTR 211, and indicated H/ACA SnoRNAs were added prior to kinase 
reaction. Samples were separated by 10% SDS-PAGE and stained with coomassie blue to detect GST-
p53 protein and autoradiography was performed to detect kinase activity. Band intensities were 
measured by densitometry. 
Fig. S9. Validation of ATRkd constructs. Indicated ATRkd constructs were cotransfected with Flag-
ATR and Flag-DGK as internal control. Anti-Flag immunoprecipitation was performed 3 days after 
transfection and IP’s were immunoblotted for Flag. 
Fig. S10. hTR overexpression in MCF7 cells. RPA performed on extracts from MCF cells 
transfected with CMV-hTR, or CMV-control constructs, cells were harvested 4 days after transfection. 
Quantification was performed by densitometry. 
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ABSTRACT
MicroRNAs (miRNAs) are small noncoding RNA molecules of 20–24 nucleotides that regulate gene expression. In animals,
miRNAs form imperfect interactions with sequences in the 39 Untranslated region (39UTR) of mRNAs, causing translational
inhibition and mRNA decay. In contrast, plant miRNAs mostly associate with protein coding regions. Here we show that human
miR-148 represses DNA methyltransferase 3b (Dnmt3b) gene expression through a region in its coding sequence. This region is
evolutionary conserved and present in the Dnmt3b splice variants Dnmt3b1, Dnmt3b2, and Dnmt3b4, but not in the abundantly
expressed Dnmt3b3. Whereas overexpression of miR-148 results in decreased DNMT3b1 expression, short-hairpin RNA-
mediated miR-148 repression leads to an increase in DNMT3b1 expression. Interestingly, mutating the putative miR-148 target
site in Dnmt3b1 abolishes regulation by miR-148. Moreover, endogenous Dnmt3b3 mRNA, which lacks the putative miR-148
target site, is resistant to miR-148-mediated regulation. Thus, our results demonstrate that the coding sequence of Dnmt3b
mediates regulation by the miR-148 family. More generally, we provide evidence that coding regions of human genes can be
targeted by miRNAs, and that such a mechanism might play a role in determining the relative abundance of different splice
variants.
Keywords: miRNA; coding region; DNMT3b; splice variants
INTRODUCTION
MiRNAs are small noncoding RNAs that have been iden-
tified as post-transciptional regulators of mRNA expression
in many multicellular organisms such as plants, insects, and
mammals. In animals, miRNAs have been shown to inhibit
mRNA translation and to decrease mRNA stability by
binding sequences in the 39UTR (Wu et al. 2006; Standart
and Jackson 2007). Perfect binding of nucelotides 2–7, the
miRNA ‘‘seed,’’ to the target mRNA is considered to play a
key role in target recognition (Doench and Sharp 2004;
Lewis et al. 2005). Binding of other miRNA nucleotides has
been suggested to be involved in mRNA repression as well,
but in this instance no perfect complementarity is required
(Grimson et al. 2007).
In plants, most described miRNAs bind the protein cod-
ing sequence (CDS) of their target mRNAs with very high-
sequence complementarity, and this induces translational
repression or RNA degradation in a way similar to RNA
interference (Llave et al. 2002; Rhoades et al. 2002; Chen
2004). The existence of miRNA-binding sites in animal
CDS has been predicted by computational approaches. By
analyzing mRNAs for conserved complementarity to the
miRNA seed sequence, about a thousand target sites were
predicted to occur in vertebrate CDSs (Lewis et al. 2005)
and a similar approach in flies predicted sites in the CDSs
as well (Stark et al. 2007). Furthermore, by combining
computational approaches and human mRNA expression
data, effective miRNA sites were detected in human CDS
(Grimson et al. 2007). In an experimental assay, let-7-mediated
repression was observed in zebrafish embryos when a let-7
target site was fused to the GFP CDS (Kloosterman et al.
2004). Furthermore, a miRNA pull-down of mRNAs and
subsequent validation of predicted CDS sites of these
mRNAs in reporter assays showed that fly miRNAs can
target CDSs (Easow et al. 2007). Yet, to our knowledge, no
functional miRNA-binding sites have been described in
mammalian coding regions.
DNA methylation is an epigenetic modification that is
involved in gene silencing, chromatin remodeling, and ge-
nome stability (Jones and Baylin 2007). In mammals, DNA
methyltransferases attach methyl groups to cytosine resi-
dues of long stretches of CpG dinucleotides (CpG islands)
that occur in repetitive sequences or in gene promoter re-
gions (Gal-Yam et al. 2008). DNMT3a and DNMT3b
have been identified as ‘‘de novo’’ methyltransferase, which
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methylate DNA during early development and gametogen-
esis (Okano et al. 1999). Inactivation of Dnmt3b results in
embryonic lethality and Dnmt3a knock-out mice die
shortly after birth (Okano et al. 1999). Although DNMT3a
and DNMT3b have overlapping functions in imprinting of
genes, DNMT3b was shown to be essential for methylation
of centromeric minor satellite repeats (Okano et al. 1999).
Furthermore, mutations in the human Dnmt3b gene have
been linked to the ICF (Immunodeficiency, Centromere in-
stability and Facial anomalies) syndrome (Xu et al. 1999).
Lymphocytes from these patients display hypomethylation
of centromeric repeat sequences, chromatin decondensation,
and genomic instability (Jeanpierre et al. 1993; Tuck-Muller
et al. 2000). In cancer, single nucleotide polymorphisms in
the Dnmt3b promoter that were hypothesized to result in
elevated Dnmt3b expression have been correlated with an
increased risk of lung cancer (Shen et al. 2002; Lee et al.
2005). Interestingly, a recent study showed direct regula-
tion of the Dnmt3a and Dnmt3b 39UTRs by miR-29 and
reduced expression of miR-29 correlated inversely with
increased expression of these Dnmts in lung cancer tissue
(Fabbri et al. 2007).
Dnmt3b has several splice variants, of which Dnmt3b1
and Dnmt3b3 are expressed most abundantly (Robertson
et al. 1999). DNMT3b1 and DNMT3b2 have been shown to
be catalytically active (Okano et al. 1998), whereas the role
of DNMT3b3 in DNA methylation is not fully understood.
Murine DNMT3b3 is catalytically inactive both in vitro
(Aoki et al. 2001) and in vivo (Chen et al. 2003); however,
the DNA methyltransferase activity of human DNMT3b3
depended on which substrate was chosen (Soejima et al.
2003; Chen et al. 2005). This discrepancy might reflect a
change in target preference since Dnmt3b3, but also
Dnmt3b4, lack a motif that could be responsible for target
recognition (Kumar et al. 1994). Interestingly, high expres-
sion of splice variant Dnmt3b4 has been associated with
DNA hypomethylation at pericentromeric satellite regions
(Saito et al. 2002). This could be a result of dominant-
negative regulation or an example of changed target pref-
erence. The latter could result in altered gene expression,
and this was indeed observed by microarray analysis in cells
that exogenously expressed Dnmt3b7, a splice variant that
was found highly expressed in cancer cells (Ostler et al.
2007). Another possibility would be that DNMT3b3 stim-
ulates DNMT3b1 catalytic activity in a similar way to
the DNMT3b-related protein DNMT3L, which also lacks
methyltransferase activity (Chen et al. 2005).
Here, we describe our finding that human miR-148
regulates DNMT3b expression through interaction with a
conserved site in its protein coding sequence. Inter-
estingly, the target site is absent in the abundantly ex-
pressed Dnmt3b3 splice variant, making it resistant to
miRNA-mediated regulation. Thus, the expression of miR-
148 changes the relative abundance of DNMT3b splice
variants.
RESULTS AND DISCUSSION
In plants, most miRNAs regulate mRNA expression by
interacting with highly homologous CDS (Rhoades et al.
2002). We identified a site in the Dnmt3b CDS (nucleotides
2384–2411) that is highly homologous to the miR-148
family (Fig. 1A). This region has the potential to interact
with all 22 nucleotides (nt) of miR-148a and miR-148b
(leaving only one gap) and therefore resembles miRNA
target interactions observed in plants. Importantly, the
target site (referred to as site #1) is conserved in rhesus,
mouse, rat, dog, horse, and armadillo Dnmt3b1, Dnmt3b2,
and Dnmt3b4, suggesting that this sequence is retained
through evolution (Fig. 1A). However, this particular se-
quence is not present in the Dnmt3b3 splice variant (Fig.
1B; data not shown). Another site (#2) that contains com-
plementarity to the miR-148 family is situated between
nucleotides 1424 and 1439 (determined using targetscanS
and RNA22) (Fig. 1B). Although it has a good match of the
miRNA seed sequence (nucleotides 2–7), which is thought
to specify miRNA targets in 39UTRs (Doench and Sharp
2004; Lewis et al. 2005), extensive complementarity such as
observed with site #1 is not seen.
Next, we designed experiments to study the regulation
of Dnmt3b by miR-148. First, we used miR-Vec-148a, a
miRNA-expression vector for ectopic expression of miR-
148a (Voorhoeve et al. 2006). Using an RNase protection
FIGURE 1. Schematic representation of putative miR-148 sites in the
Dnmt3b1 coding region. (A) miR-148a and miR-148b are highly
complementary to nucleotides 2382–2412 of human Dnmt3b. This
potential miR-148 target site is conserved in rhesus, mouse, rat, dog,
horse, and armadillo. This site is referred to as target site #1. (B)
Schematic representation of two possible miR-148 target sites in the
Dnmt3b coding region.
miR-148 targets DNMT3b protein coding region
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assay (RPA) for miR-148 in HeLa cells, which were
previously shown to be negative for miR-148 (Barad et al.
2004), transient and stable introduction of miR-Vec-148a
led to high expression of this miRNA (Fig. 2A). Second,
we determined whether we could identify cell lines that
endogenously express miR-148 by quantitative real-time
(qRT) PCR specific for mature miR-148a. We observed
high miR-148 expression in the 2102EP testicular germ-cell
line, 293T cells, Jurkat T cells, but not in HeLa, MCF-7
cells, and diploid BJ fibroblasts that were immortalized
with telomerase (Fig. 2B). Notably, the high expression
observed in the transient transfected miR-148a HeLa cells
was very similar to the endogenous expression of miR-148a
found in Jurkat cells (Fig. 2B). In contrast to miR-148a, we
were unable to detect endogenous expression miR-148b
(which was originally cloned from rat) in human cell lines
(data not shown). Third, we cotransfected miR-Vec-148a
with an expression vector containing the coding region
for Dnmt3b1 downstream of the green fluorescent protein
(GFP-Dnmt3b1) and performed immunoblotting analysis
for GFP. Notably, Dnmt3b was cloned in-frame with GFP,
which was verified by sequencing. Furthermore, the trans-
lational fusion product was detected at the appropriate size
by Immunoblotting analysis (data not shown). We ob-
served a marked reduction of 60% of GFP-DNMT3b1
expression, but not of cotransfected H2B-GFP, in cells ex-
pressing miR-148 (Fig. 2C). As expected from the sequence
similarity between miR-148a and miR-148b, a similar re-
duction of GFP-DNMT3b1 expression in cells expressing
miR-148b was observed (Fig. 2D). These results suggest
that the presence of miR-148 represses the expression of
DNMT3b1.
To determine whether the observed reduction in
DNMT3b1 expression by miR-148 is dependent on the
putative miR-148 target sites, we mutated these regions to
significantly reduce recognition by the miRNAs. Impor-
tantly, mutating these sites did not change the frame of the
fusion proteins, as was verified by sequencing and immu-
noblotting analysis (data not shown). Transient cotrans-
fection experiments revealed that mutating the highly
homologous target site #1 almost completely abrogated
miR-148-mediated regulation (Fig. 2E). However, a mutant
of target site #2, which has much less complementarity to
miR-148, still retained sensitivity to miR-148. This suggests
that miR-148 targets Dnmt3b1 through a highly comple-
mentary sequence in the Dnmt3b1 coding region.
The results above imply that the
Dnmt3b3 splice variant, which lacks
miR-148 target site #1, is resistant to
miR-148-mediated regulation.To exam-
ine this issue, we designed primers for
qRT-PCR that distinguish endogenous
Dnmt3b3 from Dnmt3b1 and other
variants that express the targeted exon
such as Dnmt3b2 and Dnmt3b4 mRNA
(Fig. 3A). This analysis revealed that
stable expression of miR-148a in HeLa
cells resulted in small but significant
reduction (P < 0.001) in Dnmt3b1 mRNA
levels of 25%, while no reduction in
Dnmt3b3 mRNA levels was observed
(Fig. 3A). Thus, the expression of miR-
148a affects the mRNA stability of
Dnmt3b1, but not Dnmt3b3, leading
to a relative increase in the abundance
of Dnmt3b3 compared with Dnmt3b1
and all other Dnmt3b splice variants
that express the targeted site.
DNMT3b protein is highly expressed
in undifferentiated embryonic stem
cells, whereas its expression level is
much reduced in somatic cells (Okano
et al. 1998). To study the effect of miR-
148a on endogenous DNMT3b protein
expression, we attempted to detect it
in several tumor cell lines using immu-
noblot analysis. In our hands, only
2102EP testicular germ-cell tumor cells
FIGURE 2. miR-148 regulates exogenous DNMT3b protein expression through interaction
with its protein coding region. (A) RPA was used to detect miR-148 levels in HeLa cells that
were transfected with miR-148, a control miRNA (Ctrl) or in a stable polyclonal pool of miR-
148a expressing cells. The protected fragments are indicated. Lane P shows the probes for
cyclophilin and miR-148a. In lane Y, yeast RNA was used as control. (B) qRT-PCR to detect
miR-148a expression was performed using the indicated cell lines. Error bars represent
standard deviation. (C) MCF-7 cells were cotransfected with either miR-Vec-148a or a miR-
Vec control, together with GFP-Dnmt3b and H2B-GFP. Whole-cell extracts were subjected to
immunoblot analysis to detect GFP. H2B-GFP was used to demonstrate equal transfection
efficiencies. Asterisk marks a nonspecific band and shows equal loading. (D,E) As described in
C. HeLa cells were transfected with the indicated constructs.
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expressed endogenous DNMT3b in sufficient amounts to
allow detection by Western blot (data not shown). Fur-
thermore, these cells express moderate levels of miR-148a
(Fig. 2B). To assess whether increasing the miR-148 level
would result in a reduced endogenous DNMT3b1 protein
level, we electroporated the miR-148 expression vector into
2102EP cells and subjected them to immunoblotting
analysis with a specific anti-Dnmt3b antibody. In line with
the results above, overexpression of miR-148a reduced
DNMT3b1 protein levels up to 70% compared with two
different miRNA control constructs (Fig. 3B). We used two
short-hairpin RNA (shRNA) constructs targeting Dnmt3b
and an expression vector for Dnmt3b1 to control for the
specificity of the Dnmt3b antibody (Fig. 3B).
Finally, we asked whether inhibition of miR-148a activity
would elevate DNMT3b1 expression. We designed two
shRNA constructs targeting the miR-148 precursor RNA.
Electroporation of 21202EP cells with these constructs
showed that one construct, miR-148kd#2, was functional
in reducing endogenous miR-148 levels as determined by
RPA analysis (Fig. 4A). Western blot analysis of cells elec-
troporated with miR-148kd#2 indeed revealed an increase in
the DNMT3b1 protein levels (Fig. 4B). We therefore con-
clude that endogenous DNMT3b1 expression is controlled
by miR-148a in 2102EP cells.
Our data reveal a novel function of miRNA-mediated
regulation. miRNA targeting of human coding regions
in addition to 39UTRs not only extends the range of poten-
tial target sites, but also allows for splice variant-specific
regulation. Significantly, different DNMT3b splice variants
might play a role in regulating
DNMT3b activity or target-site pre-
ference. This could be an additional
mechanism to the regulation of splice
variant abundance by alternative splic-
ing. Our results rule out the pos-
sibility that alternative splicing is
induced by miR-148 targeting, since
miR-148 reduced expression of exoge-
nous DNMT3b-GFP in a site-specific
manner.
It is interesting that only the
high-affinity miR-148-target site in
Dnmt3b1 was affected by miR-148. In
the future, it will be important to de-
termine whether miRNA binding to
CDS requires more complementarity
with the target than interactions with
39UTRs. Plant miRNAs interact with
high-sequence complementarity with their
target CDS eliciting, in most of the
cases, an RNA interference-mediated
cleavage of the target mRNA (Llave
et al. 2002; Rhoades et al. 2002).
Although we observed reduction of
Dnmt3b mRNA in the presence of miR-148, the reduction
was less prominent than the observed reduction on protein
levels. This suggests that miR-148 induces both trans-
lational repression and mRNA degradation of Dnmt3b1.
Further experiments should approach this point.
The mechanism by which miRNAs mediate repression is
not completely understood. Whereas some evidence exists
for interference with initiation of translation, others suggest
that miRNAs prevent the ‘‘closed loop’’ mRNA configura-
tion induced by interaction of poly(A)-binding proteins
FIGURE 3. miR-148 reduces endogenous Dnmt3b1 mRNA and protein level. (A) qRT-PCR of
either miR-Vec-148 or control (Ctrl.) transfected HeLa cells. Specific primers were used to
detect Dnmt3b1 and Dnmt3b3 as shown schematically. Error bars represent standard deviation,
n = 4 and (***) P < 0.001. (B) 2102EP cells were electroporated with the indicated constructs
and subjected to immunoblot analysis for DNMT3b and TUBULIN.
FIGURE 4. Suppression of endogenous miR-148 increases
DNMT3b1 expression. (A) miR-148a level was detected by RPA as
described in Figure 2A. (B) 2102EP cells were electroporated with
either control (Ctrl.) or miR-148kd#2 constructs and subjected to
immunoblot analysis with Dnmt3b and Rel A antibodies.
miR-148 targets DNMT3b protein coding region
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with initiation factors at the 59 cap (Standart and Jackson
2007). The latter enhances translation efficiency. miR-148
targets Dnmt3b1 z150 nt before the stop codon in the
CDS, which is near the 39UTR and the poly(A) tail.
Therefore, the location of the miR-148 target site might
allow for miRNA-mediated repression in a similar fashion
as 39UTR binding miRNAs. On the other hand, experi-
ments with miRNA target sites cloned in the 59UTR of a
luciferase construct showed miRNA-mediated repression
(Lytle et al. 2007), suggesting that repression might be
independent of the target site location. The exact mecha-
nism through which miR-148 targets Dnmt3b1 remains to
be explored.
In conclusion, we present evidence for a functional
interaction of human miR-148 with the Dnmt3b1 CDS. It
would be interesting to see whether miRNA-mediated re-
gulation of protein coding regions turn out to be a com-
mon theme in miRNA targeting of mammalian mRNAs or
the exception that confirms the rule.
MATERIALS AND METHODS
Constructs and antibodies
Dnmt3b expression constructs were cloned by PCR in pEGFP-C2
(Clontech). Dnmt3b mutant constucts were generated by site-
directed mutagenesis using PCR, and constructs were verified by
DNA sequence analysis. Mutant#1 1429TACTGCACTG1438 was re-
placed by TTCTCGTCA. Mutant#2 2398TTGTGGTGCACT2409 was
replaced by TTAGCCGCGACC. All miRNAs were expressed from
a retroviral miR-Vec vector as described before (Voorhoeve et al.
2006). We used pSuper short-hairpin constructs (Brummelkamp
et al. 2002) targeting Dnmt3b and miR-148: Dnmt3bkd#1 AGAT
GACGGATGCCTAGAG Dnmt3bkd#2 (AGGTAGGAAAGTACGT
CGC) miR-148kd#1 ACTCTGAGTATGATAGAAG miR-148kd#2
GTCAGTGCACTACAGAACT. Antibodies against Dnmt3b (H-230,
Santa Cruz), Tubulin (YL1/2, ECACC), and NFkB p65 (C-20
Santa Cruz) and GFP (a gift from J. Neefjes) were used.
Cell culture and transfection
Hela, 2102EP, 293T, MCF-7, U2OS, BJ ET primary fibroblasts
(expressing the ecotrophic receptor and human telomerase) were
grown in Dulbecco’s Modified Eagle Medium and Jurkat cells in
Iscove’s Modified Dulbecco’s Medium suplemented with 10%
fetal bovine serum. Hela cells were transfected with Fugene
(Roche) using the manufacturer’s protocol. 2102 EP cells were
transfected by electroporation as described (Agami and Bernards
2000). A Gene Pulser Xcell Electroporation System (Bio-Rad) was
used at 120 volts, 103 1.5 msec burst duration and 1 sec interval.
Immunoblotting
For Western blot analysis, whole-cell extracts were separated at
6% SDS-PAGE minigels and transferred to polyvinylidene difluor-
ide membranes (Millipore). Western blots were developed using
enhanced chemiluminescence (Amersham Biosciences). Densito-
metric quantification of Western blot assays was done by using
Tina (version 2.09f) software.
RNA isolation, RPA, and real-time RT-PCR
RNA was isolated from cells using Trizol (Invitrogen). RNase
protection assays (RPAs) were performed using the mirVana
miRNA probe construction and detection kits (Ambion) accord-
ing to the manufacturers’ protocol. A total of 5 mg of RNA was
used per assay and a ATAGAAGTCAGTGCACTACAGAACTTTG
TCTCCCTGTCTC primer was used to make a miR-148a probe.
Quantification was performed by densitometry.
cDNA was prepared from 1.5 mg of RNA using random
hexamer primers (Superscript III first-strand synthesis system
for RT-PCR, Invitrogen). Quantitative RT-PCR was performed
with a standard two-step amplification protocol of a MiniOpticon
System (Bio-Rad) apparatus using a SYBRgreen PCR master mix





b Actin forward CCTGGCACCCAGCACAAT; and
b Actin reverse GGGCCGGACTCGTCATACT.
The mirVana qRT-PCR miRNA detection kit (Ambion) was used
to detect miRNA expression by quantitative RT-PCR. Specific
miR-148a and U6 RT and PCR primers were used (Ambion) and
25 ng of RNA was used per reaction.
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Our protein-centered view of cellular 
processes is being challenged by 
findings that non-coding RNAs regulate 
development and homeostasis. Apart 
from a few examples of RNA posessing 
enzymatic activity, such as ribozymes, 
miRNAs are now known to regulate 
translation of many, if not most, proteins. 
The regulation of protein activity, such 
as described in chapter 4 for hTR, is 
also becoming a common theme in RNA 
regulation. Ever more such mechanisms 
are being discovered, leading to the 
realisation that much of our genome 
actually codes for regulatory RNAs of 
some sort (Amaral et al., 2008; Mattick, 
2007). These non-coding RNAs are 
bound by RNA binding proteins, and 
other RNAs, eventually guiding them 
to their targets. One such mechanism 
is described in chapter 3 for DND1. We 
are just beginning to understand some 
parts of these huge regulatory networks 
that we know are important for proper 
development and normal homeostasis of 
cells.
In chapter 3, I have described the 
regulatory role of the RNA binding protein 
Dead end 1 in the development of germ 
cells, as we found in zebrafish model 
systems and human cell lines. By binding 
to mRNAs, DND1 inhibits miRNA activity 
towards certain targets that are important 
in the development of germ cells. It does 
so by inhibiting access of these miRNAs 
to their target messenger RNAs through 
binding to specific sequences. In chapter 
5 we revealed a novel mode of miRNA 
mediated regulation. We identified a 
functional miRNA target sequence in the 
coding region of DNA methyl transferase 
3b, a mode of miRNA regulation thusfar only 
described in plants. Chapter 4 describes 
the elucidation of a novel function of the 
RNA component of telomerase, hTR. HTR 
levels were found to balance the activity of 
the ATR checkpoint kinase, independent of 
telomerase. Elevated hTR levels, as often 
found in tumor cells, inhibit the checkpoint 
kinase ATR, whereas a decrease in hTR 
levels induces ATR activity. Decreased 
ATR activity has been shown to induce 
fragile sites which fuel genomic instability 
and, thereby, cancer.
hTR, an oncogene fueling 
cancer without telomerase?
We have shown a genetic interaction 
between ATR and hTR and confirmed 
this in several tumor- and primary cell 
lines. An obvious question is whether this 
observed interaction is a direct one. We 
have addressed this question in several 
ways, from direct binding of labelled 
hTR to ATR, elecrophoretic mobility shift 
assays (EMSA), and direct precipitation 
of ATR from cells, detecting hTR by rt-pcr/ 
southern/qPCR. Our (unpublished) data 
suggests that ATR does have a (direct) 
binding capacity towards RNA and a 
certain specificity for hTR. Since ATR is 
a very large protein (2644 amino acids, 
~310 kDa), such analysis is difficult to 
perform in a quantitative and controlled 
way. For this reason I also constructed 
GST-tagged, overlapping, parts of the ATR 
protein and tested those for interaction 
in in	 vitro binding assays. Strikingly, we 
found interaction with hTR for the carboxy-
terminal kinase domain and one other, 
more amino-terminal part of ATR and 
not for 5 other GST-tagged partial ATR 
proteins. The kinase domains of several 
other proteins were also tested and found 
not to bind RNA. Unfortunately, mutational 
analysis and competition studies were 
not conclusive in pinpointing the residues 
of both ATR and hTR necessary for this 
interaction. Therefore, at this point, we 
conclude that ATR seems to bind RNA 
and has an increased affinity for hTR. It is 
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possible that ATR reacts more generally 
to RNA or possibly binds to the newly 
identified telomeric RNA transcripts, or 
TERRA (Azzalin et al., 2007; Schoeftner 
and Blasco, 2008). It has recently been 
shown that ATR activity is at least partially 
kept in check at telomeres by the telomeric 
protein POT1 (Denchi and de Lange, 
2007). Whether this inhibition is direct, or 
possibly through other factors, such as 
hTR, remains unknown. More sensitive 
techniques and different approaches will 
hopefully solve this issue in the future.
The gene that codes for hTR, TERC, 
is frequently amplificated in human 
cancers, leading to higher levels of hTR 
(Cao et al., 2008). Also, hTR levels are 
regulated by transcription factors SP1 
and NF-Y, and pRB at the transcriptional 
level. Additionally, the MAPK and JNK 
signalling patways appear to regulate hTR 
expression (Cairney and Keith, 2008). 
The levels of hTR can also be regulated 
by altering its stability as shown in Figure 
5A in chapter 4. This shows the increase 
in hTR levels upon expression of hTERT 
in BJ cells, which has previously been 
shown to be caused by an increase in 
stability (Yi et al., 1999). These examples 
show that hTR levels are tightly regulated 
in cells (in most cells in the absence of 
hTERT) implying another, telomerase-
independent role for hTR. As discussed 
before, hTR levels are increased both 
in mouse models and human cancers 
and correlate better to tumor grade than 
hTERT levels or telomerase activity 
in some cases (Brown et al., 1997; 
Cao et al., 2008; Dome et al., 2005; 
Maitra et al., 1999; Morales et al., 1998; 
Rushing et al., 1997; Soder et al., 1997; 
Yashima et al., 1997; Yashima et al., 
1998). The tumorigenic effects of hTERT      
overexpression rely on the expression 
of hTR, and there are a few examples 
providing evidence that overexpression 
of hTERT in the absence of hTR has anti-
tumorigenic effects (Cayuela et al., 2005; 
Gonzalez-Suarez et al., 2000).
Several oncogenic viruses have been 
shown to have an effect on telomerase 
activity and the Marek’s disease viruse 
even encodes the telomerase RNA 
(Fragnet et al., 2003; Trapp et al., 2006). 
Marek’s disease virus causes fatal 
lymphomagenesis in chickens, it contains 
two copies of the chicken telomerase 
RNA. These are thought to be picked 
up from the chicken genome during the 
virus’s evolution, as is the case for other 
known viral oncogenes such as myc, abl 
and src. Interestingly, the viral telomerase 
RNA was shown to be essential 
for Marek’s disease virus induced 
lymphomagenesis. In	 vitro studies with 
telomerase RNA overexpressing cell lines 
showed that these cells displayed several 
characteristics of transformation (Trapp 
et al., 2006). So, at least in the chicken, 
telomerase RNA can act as a classical 
oncogene. A few studies in human cells 
also suggest that an increase in hTR 
levels can cause clonal overgrowth of 
cells. Whether hTR can transform human 
cells, and therefore act as an oncogene, 
remains to be investigated.
Novel miRNA regulatory 
networks, who targets who?
The miRNA field has been developing 
very fast and its focus has shifted from 
identifying targets to real implementation 
of miRNAs in cellular networks, where 
miRNAs are one level of regulation that 
is in its turn regulated by other factors. 
In chapter 3 I have shown that Dead end 
1 is such an additional factor regulating 
the outcomes of miRNA expression. At 
present, the details of this interaction 
and other described examples in the 
literature remain unclear, it is also not fully 
understood how miRNAs themselves work 
(Bhattacharyya et al., 2006; Filipowicz et 
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al., 2008; Neumuller et al., 2008). 
The rules governing binding of miRNAs 
to their target mRNA are still very much 
unclear, although some new techniques 
involving proteomics are quickly moving 
this field ahead (Baek et al., 2008; Selbach 
et al., 2008). In animals, miRNAs utilize a 
seed sequence at their 5’ end (nt 2-8) to 
associate with 3’UTR regions of mRNAs 
to suppress gene expression by inhibiting 
translation that occasionally is associated 
with mRNA decay (Bagga et al., 2005; 
Filipowicz et al., 2008; Lim et al., 2005; 
Pillai et al., 2005). Prediction algorythms 
are widely being used but these still give 
a lot of false hits (le Sage et al., 2007). 
One of the pitfalls of these methods is the 
sole use of 3’-UTR regions for predicting 
miRNA regulation of mRNAs. As was 
shown in an experimental zebrafish assay, 
miRNAs can regulate messengers when 
their target site is located in the coding 
region (Kloosterman et al., 2004). As we 
have shown in chapter 5, miRNA 148/152 
is capable of regulating its target DNMT3b 
by binding the coding region of its mRNA. 
It may be possible that in the case of 
CDS targeting different rules apply, for 
the interaction we found has considerable 
higher sequence complementarity, as is 
also the case for plants (Rhoades et al., 
2002). Since the target site we identified 
for the miR-148/152 family is only present 
in specific DNMT3b splice variants, this 
observation might hint towards a whole 
novel concept of regulation of splice 
variant abundance for miRNAs.
DND1 shares an overall amino acid identity 
of 34% with apobec complementation 
factor (ACF) (Youngren et al., 2005). 
This protein is the essential RNA-binding 
cofactor of apolipoprotein B mRNA-
editing enzyme catalytic polypeptide-
like 1 (APOBEC1), these proteins 
together comprise the editosome witch 
converts specific cytidines to uridines 
in the apolipoprotein B transcript and 
other mRNAs. Recently, DND1 was 
found to interact with APOBEC3, a 
factor that is known to hypermutate 
cDNAs of retroviruses in human cells, 
thereby inhibiting viral replication of, for 
instance HIV (Bhattacharya et al., 2008). 
APOBEC3G has recently been described 
to derepress miRNA function on artificial 
reporter constructs in human tumor cell 
lines (Huang et al., 2007). It is unclear 
whether this function of APOBEC3G is 
important for endogenous translational 
regulation nor whether it is dependent on 
DND1 in germ cells. It will be interesting to 
test whether DND1 effects are dependent 
on APOBEC3G, or any other APOBEC 
factors, whether they target the same, 
or different transcripts, and whether they 
act synergystically or antagonistically. It 
is tempting to speculate for a function of 
DND1 or any of the APOBEC proteins in 
the repression of viral replication in germ 
cells by inhibition of the miRNA pathway 
since many viruses have been described 
to make use of miRNAs (Gottwein and 
Cullen, 2008). These are new questions 
that we will follow up in our search for the 
mechanism of DND1 function.
When DND1 is lost from primordial germ 
cells in zebrafish and mice, the germ cells 
die (Weidinger et al., 2003; Youngren et 
al., 2005). When we knocked down DND1 
in human testicular germ cell tumor lines, 
this phenotype was not immediately clear, 
although we did not perform growth nor 
apoptosis assays. It is possible that these 
tumor cells have become refractory for 
DND1 knockdown because they have 
compensated for DND1 function by 
overexpressing miRNAs, their targets, or 
both. Previously, our group described that 
in fact miR-372 is highly expressed in many 
testicular germ cell tumors (Voorhoeve et 
al., 2006). A recent study in TGCT tumor 
samples found no evidence for mutations 
of DND1 (Linger et al., 2008). To establish 
a direct link between DND1 and germ cell 
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tumors, we need to look at a correlation 
between DND1 levels and miRNAs in 
tumor samples, as also discussed by 
René Ketting (Ketting, 2007).
We need to know whether DND1 effects 
are indeed mediated through miRNAs 
and which are the target mRNAs of 
DND1. Therefore we are in the process 
of identifying the consensus sequence for 
DND1 and rescue experiments in zebrafish 
mutants for Dicer are underway.
In conclusion, the chapters presented here 
show surprising new interactions between 
non-coding RNAs and various essential 
cellular pathways. Counterbalancing the 
function of ATR may be a function of 
hTR that facilitates tumorigenesis. The 
protective function of DND1 towards 
certain miRNA targets may be important 
for the inhibition of tumorigenic miRNAs. 
These studies show that there are 
certainly more new RNA playgrounds to 
discover.
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Het vormen en in stand houden van een 
menselijk lichaam, bestaande uit grofweg 
honderdduizendmiljard cellen, uit één 
enkele bevruchte eicel, of zygote, is een 
zeer gecompliceerde taak. Hiervoor is een 
nauwe samenwerking tussen honderden 
verschillende celtypen en weefsels, 
en een strenge controle op celdeling 
nodig. Het is dan ook niet moeilijk voor 
te stellen dat er in de ontwikkeling of het 
onderhoud wel eens iets mis gaat. Zulke 
fouten worden meestal door het lichaam 
hersteld, maar soms leiden ze tot ziekten, 
zoals kanker. 
Eigenlijk zijn alle cellen in een 
multicellulair organisme altruïstisch, zij 
hebben een ondersteunende functie 
voor de geslachtscellen, die de volgende 
generatie gaan vormen. Eén van de 
fundamentele verschillen tussen normale 
cellen en kankercellen is dat kankercellen 
egoïstisch zijn. Kankercellen luisteren niet 
meer naar signalen van hun buren om te 
stoppen met delen, ze wedijveren voor 
voedingsstoffen met omliggende cellen en 
zaaien uit naar andere weefsels zonder 
zich aan de daar heersende sociale regels 
te houden en vernietigen deze weefsels 
vaak terwijl ze zich voortplanten. 
In de algemene introductie (Hoofdstuk 1) 
staat kort beschreven welke fysiologische 
veranderingen de meeste kankercellen 
hebben ondergaan. In de meeste gevallen 
liggen genetische veranderingen, ofwel 
mutaties, hieraan ten grondslag. In het 
laboratorium is het bijvoorbeeld mogelijk 
om normale cellen, na introductie van 
een beperkt aantal factoren (meestal 
in kankercellen gemuteerde genen) die 
in kankercellen gedereguleerd zijn, te 
veranderen in kankercellen. Met behulp 
van dit soort modellen kun je vaststellen 
in welke mate veranderingen die men in 
kankercellen vindt een bijdrage leveren 
aan het onstaan of  voortbestaan van deze 
cellen. Op die manier zijn bijvoorbeeld ook 
factoren te vinden die wellicht te remmen 
zijn met medicijnen, om zo de kanker te 
bestrijden.
In dit boekje wordt een aantal factoren 
beschreven die in meer of mindere mate 
een bijdrage leveren aan intracellulaire 
moleculaire signalerings-cascades die 
belangrijk zijn voor het ontstaan of de 
handhaving van kanker. In sommige 
gevallen is deze connectie niet direct 
evident. Dit komt doordat we in het 
onderzoek vaak interessante fenomenen 
tegenkomen die ons een dieper inzicht 
geven in hoe cellen werken. Uiteindelijk 
zal zo’n groter inzicht hopelijk ook leiden 
tot nieuwe inzichten voor de behandeling 
van kanker en andere ziekten. 
Hoofdstuk 4 beschrijft de studie die we 
hebben gedaan naar de rol van hTR, 
de RNA-component van telomerase, in 
de respons van cellen op DNA-schade 
(beknopt uitgelegd in hoofdstuk 1). 
Telomerase is een eiwit-RNA-complex 
dat de uiteinden van chromosomen (het 
erfelijk materiaal, met de blauwdruk van 
de werking van onze cellen) stabiliseert 
en kan verlengen. In vrijwel alle normale 
cellen in ons lichaam worden de uiteinden 
van chromosomen (de telomeren) korter, 
een proces dat na een beperkt aantal 
celdelingen leidt tot het stoppen van de 
celcyclus. Dit is als het ware een natuurlijke 
klok, of rem op de voortplantingscapaciteit 
van cellen. Kankercellen hebben deze 
rem in alle gevallen gesaboteerd om 
te kunnen blijven delen, meestal door 
meer aan te maken (overexpressie) 
van de individuele componenten van 
het telomerasecomplex, hTR en het 
telomerase eiwit. Een interessant en 
weinig bestudeerd fenomeen is dat veel 
tumoren al in een vroeg stadium de 
RNA-component hTR tot overexpressie 
brengen, terwijl telomerase en de activiteit 
van het complex afwezig of laag zijn. 
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Ook hebben vrijwel alle normale cellen 
in ons lichaam hTR, en niet telomerase. 
Door de hoeveelheid aan hTR in zowel 
normale als tumorcellen te reduceren met 
behulp van de RNA-interferentietechniek 
(RNAi) en met behulp van een aantal 
andere proeven hebben wij ontdekt dat 
hTR een telomerase-onafhankelijke rol 
in de DNA-schaderespons heeft. Een 
grotere hoeveelheid aan hTR is aanwezig 
in kankercellen en wordt in normale 
cellen aangemaakt als respons op UV-
bestraling (een specifieke vorm van DNA-
schade), dit leidt tot een onderdrukking 
van de respons op DNA-schade. Dit 
mechanisme zet deze respons in normale 
cellen uiteindelijk weer uit en werkt de 
ongebreidelde groei van de kankercellen 
in de hand doordat ze schade aan hun 
DNA negeren.
De analyse van de functie van het eiwit 
Dead End 1, beschreven in hoofdstuk 
3 kan ons iets leren over het ontstaan 
van kiemceltumoren, maar de lessen 
die we hier hebben geleerd zijn ook veel 
algemener toepasbaar. In deze studie 
hebben we een nieuwe en complexe 
manier van genregulatie aan het licht 
gebracht, die in het geval van Dead 
End 1 essentieel is voor de ontwikkeling 
van de kiemcellen. Dit zijn de cellen die 
uiteindelijk sperma en oöcyten gaan 
vormen en dus aan de basis staan van de 
volgende generatie. 
Dead End werkt op het niveau van 
boodschapper-RNA’s. Dit zijn kopieën 
van de genen die in het DNA (in de 
celkern) gecodeerd zijn en die worden 
vertaald in eiwitten (in het cytoplasma). 
Om de aanmaak van eiwitten te reguleren 
kun je bijvoorbeeld de productie van 
boodschapper-RNA’s (transcriptie) 
remmen of de vertaling naar eiwitten 
(translatie) blokkeren. MicroRNA’s zijn 
korte stukjes RNA die worden gecodeerd 
door genen in het DNA die de translatie 
van boodschapper-RNA’s remmen. Dit 
doen ze door te binden aan plaatsen in 
de boodschapper-RNA’s die gedeeltelijk 
complementair zijn. Een eiwitcomplex 
(RISC, voor RNA induced silencing 
complex) zorgt er dan voor dat de productie 
van het eiwit geremd word. MicroRNA’s 
coderen, net als het in hoofdstuk 4 
beschreven hTR-RNA-molecuul, niet 
voor de productie van een eiwit, maar 
functioneren als RNA-molecuul. Vandaar 
de naam niet-coderend RNA (non-coding 
RNA). MicroRNA’s zijn pas kortgeleden 
ontdekt, er zijn er grofweg 1000 van 
in ons genoom en er is voorspeld dat 
zij meer dan de helft van alle genen 
reguleren. Ons lab en andere labs 
hebben laten zien dat enkele microRNA’s 
als tumor-suppressors of oncogenen 
kunnen werken. Hoe microRNA’s 
precies werken en voornamelijk hoe zij 
worden gereguleerd is nog grotendeels 
onduidelijk. Onze studie naar Dead End 
laat zien dat microRNA-activiteit kan 
worden gereguleerd door RNA-bindende 
eiwitten zoals Dead End 1, zonder 
daarbij de hoeveelheid microRNA’s te 
veranderen. 
Wij hebben laten zien dat het Dead End-
eiwit bindt aan uridinerijke plaatsen in 
een aantal boodschapper-RNA’s waar het 
ervoor zorgt dat microRNA’s niet kunnen 
binden. Op deze manier zorgt Dead End 
1 dat onderdrukking door microRNA’s 
wordt opgeheven en dat de gebonden 
boodschapper-RNA’s worden vertaald 
in eiwitten. De microRNA’s blijven 
dus beschikbaar in de cel om andere 
boodschapper-RNA’s, die geen plaatsen 
hebben waar Dead End kan binden, te 
onderdrukken. Hoofdstuk 3 beschrijft 
onze studie naar de functie van Dead 
End, terwijl hoofdstuk 2 deze studie in de 
literatuur over microRNA’s en kiemcellen 
plaatst en de achtergrond en implicaties 
van onze vindingen beschrijft.
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Tot nu toe hebben alle geïdentificeerde 
humane  boodschapper-RNA’s die door 
microRNA’s worden gereguleerd hun 
bindingsplaatsen voor deze moleculen 
aan een van de uiteinden van deze RNA’s 
die niet worden getransleerd (de 3’ UTR, 
of untranslated region). In hoofdstuk 5 
beschrijven we dat de microRNA 148/152 
familie in het coderende deel van de 
DNMT3b-boodschapper-RNA bindt. Een 
van de (splice-)varianten van DNMT3b 
heeft deze microRNA bindingsplaats 
niet, met als gevolg dat deze variant ook 
niet gereguleerd wordt door microRNA 
148/152. Deze vinding breidt de 
mogelijkheden voor microRNA-doelen 
drastisch uit, daar tot nu toe alleen in de 
3’UTR’s werd gekeken naar potentiële 
bindingsplaatsen. 
De rode draad die door dit proefschrift 
getiteld “New RNA playgrounds, non-
coding RNAs and RNA-binding proteins 
control cellular processes” loopt, is non-
coderend RNA. De ontrafelde functies 
van de verschillende non-coderende 
RNA’s die hier beschreven staan laten 
zien dat het speelveld (de “playground”) 
van niet-coderende RNA’s steeds maar 
weer groter blijkt dan eerder werd 
aangenomen. In de afgelopen paar jaar 
zijn verscheidene microRNA’s en andere 
non-coderende RNA’s  gevonden die een 
rol spelen in het ontstaan van kanker en 
andere ziekten. Naar verwachting zullen 
er in de komende jaren nog veel meer 
worden gevonden. Doordat de activiteit 
van RNA’s te beïnvloeden is door middel 
van binding van vergelijkbare moleculen 
die gemakkelijk te produceren zijn en 
een hoge mate van specificiteit hebben 
zijn RNA moleculen wellicht goede 
therapeutische doelen. Preklinische testen 
hebben al uitgewezen dat het mogelijk 
is om de activiteit van microRNA’s te 
remmen in diermodellen. Het behandelen 
van ziekten met behulp van middelen die 
op RNA moleculen werken (en niet zoals 
conventionele medicijnen op eiwitten) 
vergt nog veel onderzoek, maar zal 
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